PROF. DR. R. W. HARTMANN

VERÖFFENTLICHUNGEN

1) Hartmann R. W., Kranzfelder G., v. Angerer E., Schönenberger H., Antiestrogens. Synthesis and evaluation of mammary tumor inhibiting activity of 1,1,2,2-tetraalkyl-1,2-diphenylethanes, *J. Med. Chem.* **1980**, *23*, 841-848

2) Hartmann R. W., Buchborn H., Kranzfelder G., Schönenberger H., Potential antiestrogens.Synthesis and evaluation of mammary tumor inhibiting activity of 1,2-dialkyl-1,2-bis(3'-hydroxyphenyl)ethanes, *J. Med. Chem.* **1981**, *24,* 1192-1197

2 a) Hartmann, R.W., Synthesis of new hexestrol derivatives and their evaluation of antiestrogenic and mammary tumor inhibiting activity, Journal of Cancer Research and Clinical Oncology **1981**, *99* (3), pp. A52-A53

3) Kranzfelder G., Hartmann R. W., v. Angerer E., Schönenberger H., Bogden A. E., 3,4-Bis(3'-hydroxyphenyl)hexane - A new mammary tumor-inhibiting compound, *J. Cancer Res. Clin. Oncol.* **1982**, *103*, 165-180

4) Hartmann R. W., Schönenberger H., Wrobel K.-H., 3,4-Bis(3'-hydroxyphenyl)hexane - A new mammary tumor-inhibiting compound. Studies on the mechanism of action on the DMBA-induced, hormone-dependent mammary tumor of the rat, *J. Cancer Res. Clin. Oncol.* **1982**, *103*, 241-254

5) Hartmann R. W., 3,4-bis(3'-hydroxyphenyl)hexane - A new mammary tumor inhibiting compound. Studies on the mechanism of action on the DMBA-induced, hormone-dependent mammary tumor of the rat, *Verh. Dtsch. KrebsGes.* **1983**, *4*, 156

6) Engel J., Hartmann R. W., Schönenberger H., Metahexestrol, *Drugs Future* **1983**, *8*, 413-419

7) Hartmann R. W., Tumor growth-stimulating and inhibiting effects of antiestrogens on the DMBA- induced mammary carcinoma of the ovariectomized, diethylstilbestrol-treated SD Rat. A study on the mechanism of action of antiestrogens, *Eur. J. Cancer Clin. Oncol.* **1983**, *19*, 959-964

8) Hartmann R. W., Schwarz W., Schönenberger H., Ring-substituted 1,2-dialkylated 1,2-bis(hydroxyphenyl)ethanes. 1. Synthesis and estrogen receptor binding affinity of 2,2'- and 3,3'-disubstituted hexestrols, *J. Med. Chem.* **1983**, *26*, 1137-1144

9) Hartmann R. W., Heindl A., Schönenberger H., Ring-substituted 1,2-dialkylated 1,2-bis(hydroxyphenyl)ethanes. 2. Synthesis and estrogen receptor binding affinity of 4,4'-, 5,5'-, and 6,6'-disubstituted metahexestrols, *J. Med. Chem.* **1984**, *27*, 577-585

10) Hartmann R. W., Screening procedure for the development of mammary tumour-inhibiting anti-oestrogens, *Cancer Treat. Rev.* **1984**, *11*, 155-161 (Suppl. A).

11) Hartmann R. W., Screening-Verfahren zur Auffindung von Antiöstrogenen mit Wirkung am hormonabhängigen Mammakarzinom, *Beitr. Onkol.* **1984**, *18*, 247-258

12) Hartmann R. W., Heindl A., Schwarz W., Schönenberger H., Ring-substituted 1,2-dialkylated 1,2-bis(hydroxyphenyl)ethanes. 3. Synthesis, estrogen receptor binding affinity, and evaluation of antiestrogenic and mammary tumor inhibiting activity of 2,2'-disubstituted butestrols and 6,6'- disubstituted metabutestrols, *J. Med. Chem.* **1984**, 27, 819-824

13) Hartmann R. W., TetramethylHES, *Drugs Future* **1985**, *10*, 48-49

14) Hartmann R. W., Schwarz W., Heindl A., Schönenberger H., Ring-substituted 1,1,2,2-tetraalkylated 1,2-bis(hydroxyphenyl)ethanes. 4. Synthesis, estrogen receptor binding affinity, and evaluation of antiestrogenic and mammary tumor inhibiting activity of symmetrically disubstituted 1,1,2,2-tetramethyl-1,2-bis(hydroxyphenyl)ethanes, *J. Med. Chem.* **1985**, *28*, 1295-1301

15) Hartmann R. W., Sinchai T., Kranzfelder G., Anti-proliferative effects of 1,2-diphenylethane oestrogens and anti-oestrogens on human breast cancer cells, *J. Cancer Res. Clin. Oncol.* **1985**, *110*, 17-24

16) Hartmann R. W., Heindl A., Schneider M. R., Schönenberger H., Influence of alkyl-chain fluorination on the action of mammary tumor inhibiting 2,3-bis(hydroxyphenyl)butanes and 2,3-bis(hydroxyphenyl)but-2-enes, *J. Med. Chem.* **1986**, *29*, 322-328

17) Hartmann R. W., Batzl C., Aromatase inhibitors. Synthesis and evaluation of mammary tumor inhibiting activity of 3-alkylated 3-(4-aminophenyl)piperidine-2,6-diones, *J. Med. Chem.* **1986**, *29*, 1362-1369

18) Hartmann R. W., Influence of alkyl chain ramification on estradiol receptor binding affinity and intrinsic activity of 1,2-dialkylated 1,2-bis(4- or 3-hydroxyphenyl)ethane estrogens and antiestrogens, *J. Med. Chem.* **1986**, *29*, 1668-1674

19) Schneider M. R., Hartmann R. W., Sinowatz F., Amselgruber W., Nonsteroidal antiestrogens and partial estrogens with prostatic tumor inhibiting acitivity, *J. Cancer Res. Clin. Oncol.* **1986**, *112*, 258-265

20) Batzl C., Hartmann R. W., Hemmstoffe der Aromatase. Synthese und pharmakologische Bewertung von potentiellen mammatumorhemmenden 4-Alkyl-3-(4-aminophenyl)-3-ethyl-piperidin-2,6-dionen, *Arch. Pharm. (Weinheim)* **1987**, *320*, 51-58

21) Hartmann R. W., Schönenberger H., Antitumormittel - Hormone und Antihormone. In: Kleemann A., Lindner E., Engel J. (Hrsg.) Arzneimittel-Fortschritte 1972-1985, Verlag Chemie, Weinheim **1987**, 1308-1366

22) Hartmann R. W., Batzl C., Schönenberger H., Structure-activity studies and evaluation of mammary tumor inhibiting activity of new aromatase-inhibitors of the aminoglutethimide-type, *Steroids* **1987**, *50*, 627-628

23) Hartmann R. W., Schwarz W., Schneider M. A., Engel J., Schönenberger H., D-18954. A new antiestrogen with mammary and prostatic tumor inhibiting activity, *Drugs Future* **1988**, *13*, 720-721

24) Krischke W., Hartmann R. W., Schneider, M., Schönenberger H., A simple method of delayed processing of tumor tissue in a soft agar clonogenic assay, *J. Cancer Res. Clin. Oncol.* **1988**, *114*, 170-176

25) Hartmann R. W., vom Orde H.-D., Heindl A., Schönenberger H., N-(4-hydroxyphenyl)-N-(1,1,1-trifluor-2-propyl)-4-hydroxybenzamid: Synthese und pharmakologische Bewertung eines neuen Antiestrogens, *Arch. Pharm. (Weinheim)* **1988**, *321*, 497-501

26) Hartmann R. W., Batzl C., Mannschreck A., Seydel J. K., New aromatase inhibitors. QSAR and evaluation of mammary tumor inhibiting activity. In: van der Goot H., Pallos L., Timmermann H. (Eds.) Trends in Medicinal Chemistry 1988, Elsevier, Amsterdam **1989**, 821-838

27) Schönenberger H., Gust R., Karl J., Spruß T., Schneider M. R., Hartmann R. W., Batzl C., Schertl S., Engel J., Lux F., Trebert-Haeberlin S., Rezeptorgebundene Chemotherapie. In: Antiöstrogene in Forschung und Klinik, aus der Reihe Aktuelle Onkologie, Zuckschwerdt Verlag, München **1989**, 71-86

28) Hartmann R. W., Estrogenabhängige Tumoren und ihre Behandlung, *Pharm. Ztg.* **1989**, *134,* 2629-2638

28 a) Schwarz, W., Hartmann, R.W., Engel, J., Schneider, M.R., Schonenberger, H. ,Ester derivatives of the mammary-tumor-inhibiting antiestrogen 2,3-bis(2-fluoro-4-hydroxyphenyl)-2,3-dimethylbutane, In: Journal of Cancer Research and Clinical Oncology **1989**, *115* (2), 161-165

29) Schönenberger H., Gust R., Karl J., Spruß T., Schneider M. R., Hartmann R. W., Batzl Ch., Schertl S., Engel J., Lux F., Trebert-Haeberlin S., Chancen und Stand der Entwicklung neuer antineoplastischer Substanzen II. In: Dengler H.J., Schmitt C.G.: Klinische Pharmakologie und Onkologie, Gustav Fischer Verlag, Stuttgart, **1990**, 255-278

30) Hartmann R. W., Batzl C., Mannschreck A., Pongratz T., Stereoselective aromatase inhibition by the enantiomers of 3-cyclohexyl-3-(4-aminophenyl)-2,6-piperidinedione. In: Holmstedt B., Frank H., Testa B.: Chirality and Biological Activity, Alan R. Liss, New York **1990**, 185-190

31) Hartmann R. W., vom Orde H.-D., Schönenberger H., Antiestrogene N-(4-Hydroxyphenyl)-N-(1,1,1-trifluor-2-propyl)-4-hydroxybenzamide: Beeinflussung der Wirkung durch hydrophobe Reste in ortho-Position des Benzamidfragments, *Arch. Pharm. (Weinheim)* **1990**, *323*, 73-78

32) Schwarz W., Hartmann R. W., Engel J., Schneider M. R., Schönenberger H.; Cytotoxic ester derivatives of the mammary tumor inhibiting antiestrogen 2,3-bis(2-fluoro-4-hydroxyphenyl)-2,3-dimethylbutane, *Arch. Pharm. (Weinheim)* **1990**, *323*, 121-124

32 a) Hartmann, R.W., Enzyme inhibitors in the treatment of malignant tumors, *Archiv der Pharmazie* **1990**, *323* (8), pp. 529-530

33) Schwarz W., Hartmann R. W., Schönenberger H.; Potentielle Antiöstrogene vom Typ des 1,2-Diphenyl-1-pyridyl-but-1-ens, Teil 1: Synthese, *Arch. Pharm. (Weinheim)* **1991**, *324*, 223-229

34) Schwarz W., Hartmann R. W., Schönenberger H.; Potentielle Antiöstrogene vom Typ des 1,2-Diphenyl-1-pyridyl-but-1-ens, Teil 2: Biologische Prüfung, *Arch. Pharm. (Weinheim)* **1991**, *324*, 231-234.

35) Bayer H., Hartmann R. W., Neue Hemmstoffe der Aromatase. Synthese und biologische Aktivität Pyridyl-substituierter Phenanthrenonderivate, *Arch. Pharm. (Weinheim)* **1991**, *324*, 833-836

36) Bayer H., Hartmann R. W., Pyridyl-substituierte Tetralonderivate. Eine neue Klasse nichtsteroidaler Aromatase-Inhibitoren, *Arch. Pharm. (Weinheim)* **1991**, *324*, 815-820

37) Bayer H., Batzl C., Hartmann R. W., Mannschreck A., New aromatase inhibitors. Synthesis and biological activity of pyridyl-substituted tetralone derivatives, *J. Med. Chem.* **1991**, *34*, 2685-2691

38) Hartmann R. W., Batzl C., Synthesis and evaluation of 4-alkylanilines as mammary tumor inhibiting aromatase inhibitors, *Eur. J. Med. Chem.* **1992**, *27*, 537-544

39) Hartmann R. W., Batzl C., Pongratz T., Mannschreck A., Synthesis and aromatase inhibition of 3-cycloalkyl-substituted 3-(4-aminophenyl)piperidine-2,6-diones, *J. Med. Chem.* **1992**, *35*, 2210-2214

40) Hartmann R. W., Development of a postmenopausal rat mammary tumor model, *Pharm. Pharmacol. Lett.* **1992**, *2*, 146-149

41) Hartmann R. W., Grün G., Bartz U., Palzer M., Evaluation of the racemate and the enantiomers of a new highly active and selective aromatase inhibitor of the aminoglutethimide type, *J. Steroid Biochem. Mol. Biol.* **1992**, *43*, 641-648

42) Bednarski P. J., Hartmann R. W., Synthesis and evaluation of sulfur-containing glutethimide derivatives for aromatase and desmolase inhibitory activity, *Arch. Pharm. (Weinheim)* **1993**, *326*, 391-394

43) Herrmann S. M., Reichert M., Hartmann R. W., Entwicklung eines Hemmassays und Synthese von nicht-steroidalen Inhibitoren der NADPH: Δ^4-3-Oxosteroid-5α-Oxidoreduktase (5α-Reduktase). In: Hirschelmann R. (Hrsg.) Entzündung und verwandte Reaktionen – neue Erkenntnisse - neue Wirkstoffe, Jenapharm-Verlag, Jena **1993**, 62-69

44) Grün G., Hartmann R. W., Hochaktive nichtsteroidale Aromatase-Inhibitoren: In vitro und in vivo Untersuchungen zur Selektivität und tumorhemmenden Aktivität. In: Hirschelmann R. (Hrsg.) Entzündung und verwandte Reaktionen - neue Erkenntnisse - neue Wirkstoffe, Jenapharm-Verlag, Jena **1993**, 204-214

45) Sergejew T. F., Hartmann R. W., Sexualhormonspiegel-reduzierende Platinkomplexe: Untersuchungen zum Wirkungsmechanismus. In: Hirschelmann R. (Hrsg.) Entzündung und verwandte Reaktionen - neue Erkenntnisse - neue Wirkstoffe, Jenapharm-Verlag, Jena **1993**, 215-222

46) Hartmann R. W., Bayer H., Grün G., Aromatase inhibitors. Syntheses and structure-activity studies of novel pyridyl-substituted indanones, indans and tetralins, *J. Med. Chem.* **1994**, *37*, 1275-1281

47) Sergejew T., Hartmann R. W., Pyridyl substituted benzocycloalkenes: New inhibitors of 17α-hydroxylase / 17,20-lyase (P450 17α), *J. Enz. Inhib.* **1994**, *8*, 113-122

48) Hartmann R. W., Selective inhibition of steroidogenic P450 enzymes: current status and future perspectives, *Eur. J. Pharm. Sci.* **1994**, *2*, 15-16

49) Hartmann R. W., Reichert M., Göhring S., Novel 5α-reductase inhibitors. Syntheses and structure-activity studies of 5-substituted 1-methyl-2-pyridones and 1-methyl-2-piperidones, *Eur. J. Med. Chem.* **1994**, *29*, 807-817

50) Mitrenga M., Hartmann R. W., N-Oxide formation causes loss of aromatase inhibitory activity of pyridyl substituted tetrahydronaphthalenes, *Eur. J. Med. Chem.* **1995**, *30*, 241-244

51) Kattner L., Göhring S., Hartmann R. W., Synthesis and biochemical evaluation of (carbamoyl-alkenyl)phenyloxy carboxylic acid derivatives as non-steroidal 5α-reductase inhibitors, *Arch. Pharm. (Weinheim)* **1995**, *328*, 239-245

52) Hartmann R. W., Bayer H., Grün G., Sergejew T., Bartz U., Mitrenga M., Pyridyl-substituted tetrahydrocyclopropa[a]naphthalenes: highly active and selective inhibitors of P450 arom, *J. Med. Chem.* **1995**, *38*, 2103-2111

53) Njar V. C. O., Hartmann R. W., Robinson C. H., Synthesis of 6α,7α- and 6β,7β - aziridinoandrost-4-ene-3,17-diones and related compounds: potential aromatase inhibitors,

J. Chem. Soc. Perkin Trans. I **1995**, 985-991

54) Njar V. C. O., Grün G., Hartmann R. W., Evaluation of 6,7-aziridinyl steroids and related compounds as inhibitors of aromatase (P-450$_{arom}$), *J. Enz. Inhib.* **1995**, *9*, 195-202

55) Hartmann R. W., Wächter G. A., Sergejew T., Würtz R., Düerkop J., 4,5-Dihydro-3-(2-pyrazinyl)naphtho[1,2-c]pyrazole: A potent and selective inhibitor of steroid-17β-hydroxylase-C17,20-lyase (P450 17), *Arch. Pharm. (Weinheim)* **1995**, *328*, 573-575

56) Ledergerber D., Hartmann R. W., Development of a screening assay for the *in vitro* evaluation of thromboxane A2 synthase inhibitors, *J. Enz. Inhib.* **1995**, *9*, 253-261

57) Njar V. C. O., Düerkop J., Hartmann R. W., Novel 19-(cyclopropylamino)-androst-4-en-3,17-dione: A mechanism-based inhibitor of aromatase, *J. Enz. Inhib.* **1995**, *10*, 47-56

58) Hector M., Hartmann R. W., Njar V. C. O., Pyridinium dichromate: A novel reagent for the oxidation of steroidal Δ^5-3β-alcohols to the corresponding Δ^4-3,6-diketones, *Synth. Commun.* **1996**, *26*, 1075-1082

59) Njar V. C. O., Düerkop J., Hartmann R. W., Synthesis of 10β-(1'-azirinyl)estr-4-en-3,17-dione as an aromatase inhibitor, *Steroids* **1996**, *61*, 138-143

60) Wächter G. A., Hartmann R. W., Sergejew T., Grün G. L., Ledergerber D., Tetrahydronaphthalenes: Influence of heterocyclic substituents on inhibition of steroidogenic enzymes P450 arom and P450 17, *J. Med. Chem.* **1996**, *39*, 834-841

61) Hartmann R. W., Frotscher M., Ledergerber D., Wächter G. A., Grün G. L., Sergejew T. F. Synthesis and evaluation of azole-substituted tetrahydronaphthalenes as inhibitors of P450 arom, P450 17 and P450 TxA_2, *Arch. Pharm. Pharm. Med. Chem.* **1996**, *329*, 251-261

62) Njar V. C. O., Hector M., Hartmann R. W., 20-Amino- and 20,21-aziridinyl pregnene steroids: development of potent inhibitors of 17α-hydroxylase/C17,20-lyase (P450 17), *Bioorg. Med. Chem.* **1996**, *4*, 1447-1453.

63) Hartmann R. W., Mark M., Soldati F., Inhibition of 5α-reductase and aromatase by PHL-00801 (Prostatonin®), a combination of PY102 (Pygeum africanum) and UR102 (Urtica dioica) extracts, *Phytomedicine* **1996**, *3*, 121-128.

64) Sergejew T. F., Hartmann R. W., Effect of a diphenylethylenediamine platinum complex on steroidogenesis in rats, *J. Steroid Biochem. Mol. Biol.* **1996**, *58*, 243-248

65) Ledergerber D., Frotscher M., Hartmann R. W., Novel highly active thromboxane A_2 synthase inhibitors void of carboxylic groups, *Arch. Pharm. Pharm. Med. Chem.* **1997**, *330*, 3-5

66) Ducrey B., Marston A., Göhring S., Hartmann R. W., Hostettmann K., Inhibition of 5α-reductase and aromatase by the ellagitannins oenothein A and oenothein B from *epilobium* species, *Planta Med.* **1997**, *63*, 111-114

67) Le Borgne M., Marchand P., Duflos M., Delevoye-Seiller B, Piessard-Robert S., Le Baut G., Hartmann R.W., Palzer M., Synthesis and *in vitro* evaluation of 3-(1-azolylmethyl)-1*H*-indoles and 3-(1-azolyl-1-phenylmethyl)-1*H*-indoles as inhibitors of P 450 arom, *Arch. Pharm. Pharm. Med. Chem.* **1997**, *330*, 141-145

68) Le Borgne M., Marchand P., Duflos M., Piessard-Robert S., Le Baut G, Ahmadi M., Palzer M., Hartmann R. W., Comparison of the in vitro aromatase inhibitory activity for 3-(azolylmethyl)-1*H*-indoles, *Pharm. Sci.* **1997**, *3*, 279-281

69) Hartmann R. W., Frotscher M., Grün G. L., Hector M., Ledergerber D., Mitrenga M., Sergejew T., Wächter G. A., Metabolism of endobiotics and therapeutic aspects of P450 inhibitors. In Awouters F. (Ed.) Proceedings, 14th International Symposium for Medicinal Chemistry, Elsevier Scientific Publishers, Amsterdam **1997**, 109-116

69a) Becker H., Hartmann R.W., Kallmayer H.-J., Lehr, C.-M., Loth H., Maurer H. H., Die Pharmazie an der Universität des Saarlandes, *Pharm.unserer Zeit* **1997**, *26*, 199-201

70) Zhuang, Y., Zapp J., Hartmann R.W., Synthesis of Z- and E-1-methyl-2-(1-hydroximinoethyl)-6-methoxy-3,4-dihydronaphthalene and evaluation as inhibitors of 17α-hydroxylase-C17,20-lyase (P450 17), *Arch. Pharm. Pharm. Med. Chem.* **1997**, *330*, 359-361

70 a) Ledergerber, D., Frotscher, M., Hartmann, R.W. Novel highly active thromboxane A2 synthase inhibitors devoid of carboxylic groups, Archiv der Pharmazie **1997**, 330 (1-2), pp. 3-5

71) Huang, Y., Hartmann R.W., The improved preparation of 7,8-dihydro-quinoline5(*6H*)-one and 6,7-dihydro-*5H*-1-pyrindin-5-one, *Synth. Comm.* **1998**, *28*, 1197-1200

72) Baston, E., Hartmann R.W., A new route to 6-aryl-substituted 3,4-dihydronaphthalene derivatives via Pd (O)-catalyzed cross-coupling reaction of aryl zinc chlorides with an aryl triflate, *Synth. Comm.* **1998**, *28*, 2725-2729

73) Zhuang, Y., Hartmann, R.W., Synthesis of novel oximes of 2-aryl-6-methoxy-3,4-dihydronaphthalene and evaluation as inhibitors of of 17α-hydroxylase-C17,20-lyase (P450 17), *Arch. Pharm. Pharm. Med. Chem.* **1998**, *331*, 36-40

74) Marchand, P., Le Borgne M., Duflos, M., Robert-Piessard, S., Le Baut, G., Ahmadi, M., Hartmann, R.W., Palzer M., 3-(azolylmethyl)-1*H*-idoles as selective P450 aromatase inhibitors, *Pharm. Pharmacol. Commun.* **1998**, *4*, 211-218

75) Dannhardt, G., Flemmer, L., Hartmann, R.W., Kleber A. and Schulze,E., Spectrofluorimetrical quantification of malondialdehyde for evaluation of cyclooxygenase-1/thromboxane synthase inhibition, *Arch. Pharm. Pharm. Med. Chem.* **1998**, *331*, 359-364

76) Le Borgne, M., Marchand, P., Delovoye-Seiller, B., Robert, J.-M., Robert-Piessard, S., Le Baut G., Hartman R.W., Palzer, M., New selective nonsteroidal aromatase inhibitors: Synthesis and inhibitory activity of 2,3 or 5-(α-azolybenzyl)-1*H*-indoles, *Bioorg. Med. Chem. Lett.* **1999**, *9*, 333-336

77) Wachall, B.G., Hector, M., Zhuang, Y., Hartmann, R.W., Imidazole substituted biphenyls - a new class of highly potent and in vivo active inhibitors of P450 17 as potential therapeutics for treatment of prostate cancer, *Bioorg. Med. Chem.* **1999**, *7*, 1913-1924

78) Zhuang, Y., Hartmann, R.W., Synthesis and evaluation of azole-substituted 2-aryl-6-methoxy-3,4-dihydronaphthalenes and -naphthalenes as inhibitors of 17 α-hydroxylase-C17,20-lyase (P450 17), *Arch. Pharm. Pharm. Med. Chem.* **1999**, *332*, 25-30

79) Baston, E., Hartmann, R.W., N-substituted 4-(5-indolyl)benzoic acids. Synthesis and evaluation of steroid 5α-reductase type I and II inhibitory activity, *Bioorg. Med. Chem.* Lett. **1999**, *9*, 1601-1606

80) Hartmann, R.W., Frotscher, M., 1-Imidazolylcarbonyloxy-substituted tetrahydroquinolines and pyridines: Synthesis and evaluation of P450 TxA2 inhibition, *Arch. Pharm. Pharm. Med. Chem.* **1999**, *332*, 358-362

81) Haider, N., Hartmann, R.W., Steinwender, A., Synthesis of 2-[2-(1-imidazolyl)ethyl]]-4-phenylcycloalka[*g*]]phthalazin-1(2*H*)-ones as thromboxane A_2 synthase inhibitors, *Arch. Pharm. Pharm. Med. Chem.* **1999**, *332*, 408-409

81a) LeBorgne, M., Loquet, D., Na, Y.M., Robert-Piessard, S., Le Baut, G., Hartmann, R.W., Palzer, M., New 7-(α-azolylbenzyl)-indoles and indolines acting as P450 aromatase inhibitors, Journal of Pharmacy and Pharmacology **1999**, *51* (SUPPL.), pp. 113

82) Zhuang, Y., Wachall, B.G., Hartmann, R.W., Novel imidazolyl and triazolyl substituted biphenyl compounds: Synthesis and evaluation as nonsteroidal inhibitors of human 17 α-hydroxylase-C17,20-lyase(P450 17), *Bioorg. Med. Chem.* **2000**, *8*, 1245-1252

83) Jacobs, C., Frotscher, M., Dannhardt, G., Hartmann, R.W., 1-Imidazolyl(alkyl)-substituted di- and tetrahydroquinolines and analogues: Syntheses and evaluation of dual inhibitors of thromboxane A_2 synthase and aromatase, *J. Med. Chem.* **2000**, *43*, 1841-1851

84) Picard, F., Baston, E., Reichert, W., Hartmann, R.W., Synthesis of N-substituted piperidine-4-(benzylidene-4-carboxylic acids) and evaluation as inhibitors of steroid-5 α-reductase type 1 and 2, *Bioorg. Med. Chem.* **2000**, *8*, 1479-1487

85) Hartmann, R.W., Reichert, M., New nonsteroidal steroid 5α-reductase inhibitors. Syntheses and structure-activity-studies on carboxamide phenylalkyl-substituted pyridones and piperidones, *Arch. Pharm. Pharm. Med. Chem.* **2000**, *333*, 145-153

86) Reichert, W., Jose, J., Hartmann, R.W., 5 α-reductase in intact DU145 cells: Evidence for isozyme I and evaluation of novel inhibitors, *Arch. Pharm. Pharm. Med. Chem.* **2000**, *333*, 201-204

87) Le Borgne, M., Duflos, M., Le Baut, G., Nicholls, P.J., Hartmann R.W., Synthesis and biological evaluation of indole derivatives acting as anti-inflammatory or antitumoral drugs, *Ann. Pharm. Fr.* **2000**, *58*, 316-320

88) Baston, E., Palusczak, A., Hartmann, R.W., 6-Substituted 1*H*-quinolin-2-ones and 2-methoxy-quinolines: Synthesis and evaluation as inhibitors of steroid 5□-reductases type 1 and 2, *Eur. J. Med. Chem.* **2000**, *35*, 931-940

89) Hartmann, R.W., Hector, M., Haidar, S., Ehmer, P., Jose, J., Synthesis and evaluation of novel steroidal oximes as inhibitors of P450 17 (17α-hydroxylase / C17-20-lyase) and 5□-reductase 1 and 2, *J. Med. Chem.* **2000**, *43*, 4266-4277

90) Hartmann, R.W., Hector M., Wachall, B.G., Palusczak, A., Palzer, M., Huch V., Veith, M., Synthesis and evaluation of 17-aliphatic heterocycle substituted steroidal inhibitors of 17 α-hydroxylase / C17,20-lyase (P450 17), *J. Med. Chem.* **2000**, *43*, 4437-4445

91) Kleber, A., Hartmann, R.W., Jose. J., Development of an improved in vitro model to study the adhesion of tumor cells to the basement membrane, *Pharm. Pharmacol. Lett.* **2000**, *10*, 55-58

92) Ehmer, P.B., Jose, J., Hartmann, R.W., Development of a simple and rapid assay for the evaluation of inhibitors of human 17 α-hydroxylase-$C_{17,20}$-lyase (P450c17) by coexpression of P450c17 with NADPH-cytochrome-P450-reductase in Escherichia coli, *J. Steroid Biochem. Mol. Biol.* **2000**, *75*, 57-63

93) Reichert, W., Hartmann, R.W., Jose, J., Stable expression of the human 5α-reductase - isoenzymes type I and type II in HEK293 cells to identify dual and selective inhibitors, *J. Enz. Inhib.* **2001**, *16*, 47-53

94) Recanatini, M., Bisi, A., Cavalli, A., Belluti, F., Gobbi, S., Rampa, A., Valenti, P., Palzer, M., Palusczak, A., Hartmann, R.W., A new class of non steroidal aromatase inhibitors: Design and synthesis of chromone and xanthone derivatives, and inhibition of P450 enzymes aromatase and 17 α-hydroxylase/C17,20-lyase, *J. Med. Chem.* **2001**, *44*, 672-680

95) Reichert, W., Michel, A., Hartmann R.W., Jose, J., Stable expression of human 5α-reductase type II in COS1 cells due to chromosomal gene integration: a novel tool for inhibitor identification, *J. Steroid Biochem. Mol. Biol.* **2001**, *78*, 275-284

96) Kleber, A., Hartmann, R.W., Jose, J., No effect of thromboxane A_2 on the attachment of tumor cell lines MDA MB 231, DU145, and U937 to the basement membrane in an in-vitro model, *J. Cancer Res. Clin. Oncol*. **2001**, *127*, 751-754

97) Schertl, S., Hartmann, R.W., Batzl-Hartmann, C., Schlemmer, R., Spruß, T., Bernhardt, G., Gust, R., Schönenberger, H., 1-(2,6-Dichloro-4-hydroxyphenyl)-2-phenylethanes - new biological response modifiers for the therapy of breast cancer. Synthesis and evalulation of estrogenic/antiestrogenic properties, *Arch. Pharm. Pharm. Med. Chem.* **2001**, *334*, 125-137

98) Baston, E., Klein, C.D.P., Grimminger, W., Hebecker, N., Hartmann, R.W., Synthesis, evaluation and QSAR studies of highly potent aromatase inhibitors of the piperidinedione type, *Anti Cancer Drug Des.* **2001**, *16*, 37-47

99) Haidar, S., Klein, C.D.P., Hartmann, R.W., Synthesis and evaluation of steroidal hydroxamic acids as inhibitors of P450 17 (17 α-hydroxylase/C17-20-lyase), *Arch. Pharm. Pharm. Med. Chem.* **2001**, *334*, 138-140.

100) Hartmann, R. W., CYP-17-Inhibitoren: Steroidomimetika zur Behandlung des Prostatakarzinoms, *Pharm. Ztg.* **2001**, *146*, 2285-2289

101) Hartmann, R.W., Die rationale Entwicklung eines Hemmstoffs von CYP 17, einem neuartigen Target zur Behandlung des Prostatacarcinoms, *Magazin Forschung, UdS* **2001**, *2*, 2-9

102) Lehr, C.-M., Hartmann, R.W., Lenhof, H.-P., Das virtuelle Biolabor, *Pharm. Ztg.* **2001**, *146*, 2541-2543

103) Haidar, S., Ehmer, P.B., Hartmann, R.W., Novel Steroidal Pyrimidyl Inhibitors of P450 17 (17 α-hydroxylase/C17-20-Lyase), *Arch. Pharm. Pharm. Med. Chem.* **2001**, 334, 373-374

103a) Hartmann, R.W., CYP-17 inhibitors: Steriod agonist for the treatment of prostate carcinoma[Steroidomimetika zur behandlung des prostatakarzinoms] Pharmazeutische Zeitung **2001,** 146 (27), pp. 11-15

103 b) Hartmann, R.W., Klein, C. Archiv der Pharmazie - Pharmaceutical and Medicinal Chemistry: Editorial, Archiv der Pharmazie*,* **2001***, 334* (2), pp. 33

104) Salem, O.I.A., Schulz, T., Hartmann, R.W., Synthesis and biological evaluation of 4-(4-alkyl- and Phenylaminocarbonyl)benzoyl)benzoic acid derivatives as non-steroidal inhibitors of steroid 5 α-reductase isozymes 1 and 2, *Arch. Pharm. Pharm. Med. Chem.* **2002**, *335*, 1-6

105) Hartmann, R.W., Ehmer, P. B., Haidar, S., Hector, M., Jose, J., Klein, C.D.P., Seidel, S. B., Sergejew, T., Wachall, B. G., Wächter, G. A., and Zhuang Y., Review: Inhibition of

CYP 17, A new strategy for the treatment of prostate cancer, *Arch. Pharm. Pharm. Med. Chem.* **2002**, *335*, 119-128

106) Picard, F., Schulz, T., Hartmann, R.W., 5-Phenyl substituted 1-methyl-2-pyridones and 4'-substituted biphenyl-4-carboxylic acids. Synthesis and evaluation as inhibitors of steroid-5 α-reductase type 1 and 2, *Bioorg. Med. Chem.* **2002**, *10*, 437-448

107) Ehmer, P.B., Bureik, M., Bernhardt, R., Müller, U., Hartmann, R..W., Development of a test system for inhibitors of human aldosterone synthase (CYP11B2): screening in fission yeast and evaluation of selectivity in V79 cells, *J. Steroid Biochem. Mol. Biol.* **2002**, *81*, 173-179

108) Picard, F. and Hartmann, R.W., *N*-substituted 4-(4-carboxyphenoxy)benzamides. Synthesis and evaluation as inhibitors of steroid-5 α-reductase type 1 and 2, *J. Enzym. Inhib. Med. Chem.* **2002**, *17*, 187-196

109) Picard, F., Barassin S., Mokhtarian, A., Hartmann, R.W., Synthesis and evaluation of 2'-substituted 4-(4'-carboxy- or 4'-carboxymethylbenzylidene)-N-acylpiperidines: highly potent and *in vivo* active steroid 5 α-reductase type 2 inhibitors, *J. Med. Chem.* **2002**, *45*, 3406-3417

110) Haidar, S. and Hartmann, R.W., C16 and C17 substituted derivatives of pregnenolone and progesterone as inhibitors of 17 α-hydroxylase-C17,20-lyase: synthesis and biological evaluation, *Arch. Pharm. Pharm. Med. Chem.* **2002**, 335, 526-534

111) Baston, E., Salem, O.I.A. and Hartmann, R. W., 6-substituted 3,4-dihydro-naphthalene-2-carboxylic acids: synthesis and structure-activity studies in a novel class of human 5 α reductase inhibitors, *J. Enz. Inhib. Med. Chem.* **2002**, *17*, 303-320

111a) Salem, O.I.A., Schulz, T., Hartmann, R.W. Hydrogels formed by crosslinked poly(vinyl alcohol) as sustained drug delivery systems, Archiv der Pharmazie **2002***, 335* (2-3), pp. 89-93

112) Mathur, S., Hassel, M., Steiner, F., Hollemayer, K., Hartmann, R.W., Development of a new approach for screening combinatorial libraries using MALDI-TOF-MS and HPLC-ESI-MS/MS, *J. Biomol. Screening* **2003**, *8*, 136-148

113) Hartmann, R.W., Müller, U., Ehmer, P.B., Discovery of selective CYP11B2 (aldosterone synthase) inhibitors for the therapy of congestive heart failure and myocardial fibrosis, *Eur. J. Med. Chem.* **2003**, *38*, 363-366

114) Baston, E. Salem, O.I.A., Hartmann, R.W., Cyclohex-1-ene carboxylic acids: synthesis and biological evaluation of novel inhibitors of human 5α reductase, *Arch. Pharm. Pharm. Med. Chem.* **2003**, *336*, 31-38

115) Haidar, S., Ehmer P.B., Barassin, S., Batzl-Hartmann, C., Hartmann, R.W., Effects of novel 17 α-hydroxylase/C17, 20-lyase (P450 17, CYP 17) inhibitors on androgen biosynthesis *in vitro* and *in vivo*, *J. Steroid. Biochem. Mol. Biol.* **2003**, *84*, 555-562.

116) Leroux, F., Hutschenreuter, T., Charrière, C., Scopelliti, R., Hartmann, R.W., *N*-(4-Biphenylmethyl)imidazoles as potential therapeutics for the treatment of prostate cancer: metabolic robustness due to fluorine substition?, *Helv. Chim. Act.* **2003**, *86*, 2671-2686.

117) Marchand, P., Le Borgne, M., Palzer, M., Le Baut, G., Hartmann R.W., Preparation and pharmacological profile of 7-(α-Azolylbenzyl)-1*H*-Indoles and indolines as new aromatase inhibitors, *Bioorg. Med. Chem. Lett.* **2003**, *13*, 1553-1555

118) Aboul-Enein, H.Y., Hefnawy M.M., Ehmer, P.B., Hartmann, R.W., Enantiomeric resolution of some human aldosterone synthase[CYP 11 B2]inhibitors on derivatized polysaccharide chiral stationary phases, *J. Sep. Sci.* **2003**, *26*, 1455-1458

119) Clement, O.O., Freeman, C.M., Hartmann, R.W., Palusczak A., Handratta, V.D., Vasaitis, T.S., Brodie, A.M.H., Njar, V.C.O., Three dimensional pharmacophore modeling of human CYP17 inhibitors: Potential agents for prostate cancer therapy, *J. Med. Chem.* **2003**, *46*, 2345-2351

120) Hutschenreuter, T.U., Ehmer, P.B., Hartmann, R.W., Synthesis of hydroxy derivatives of highly potent non-steroidal CYP 17 inhibitors as potential metabolites and evaluation of their activity by a non cellular assay using recombinant human enzyme, *J. Enz. Inhib. Med.Chem.* **2004**, *19*, 17-32

121) Aboul-Enein, H.Y., Kladna, A., Kruk, I., Lichszteld, K., Marchlewicz, M., Michalska, T., Salem, O.I.A., Hartmann, R.W., Prooxidant and antioxidant action of 4-(4-phenoxybenzoyl)benzoic acid derivatives, *Biopolymers* **2004**, *73*, 631-639

122) Mathur, S., Picard, F., Dossou, U., Barassin, C., Seidel, S.B., Kang, M.J., Hartmann, R.W., Evaluation of cell permeation of a potent 5α-reductase inhibitor using MALDI-TOF MS, *J. Enz. Inhib. Med. Chem.* **2004**, *19*, 425-429

123) Hartmann, R.W., Palusczak, A., Lacan, F., Ricci, G., Ruzziconi, R., CYP 17 and CYP 19 inhibitors. Evaluation of fluorine effects on the inhibiting activity of regioselectively fluorinated 1-(naphthalen-2-ylmethyl)imidazoles, *J. Enz. Inhib. Med. Chem.* **2004**, *19*, 145-155

124) Neugebauer, A., Klein, C.D.P., Hartmann, R.W., Protein-dynamics of the putative HCV receptor CD81 large extracellular loop, *Bioorg. Med. Chem.Lett.* **2004**, *14*, 1765-1769

125) Haider, S., Hartmann, R.W., Inhibition of CYP 17, Potential treatment of prostate cancer, *Arab J. Pharm. Sci.* **2004**, *2*, 59-76

126) Gupta, R.B., Jindal, D.P., Jit, B., Narang, G., Palusczak, A., Hartmann, R.W., Synthesis and evaluation of a dimer of 2-(4-pyridylmethyl)-1-indanone as a novel nonsteroidal aromatase inhibitor, *Arch. Pharm. Pharm. Med. Chem.* **2004**, *337*, 398-401

127) Schertl, S., Hartmann, R.W., Batzl-Hartmann, C., Bernhardt, G., Spruß, T., Beckenlehner, K., Koch, M., Krauser, R., Schlemmer, R., Gust, R., Schönenberger, H., [1,2-Bis(2,6-difluoro-3-hydroxyphenyl)ethylenediamine]platinum(II) complexes, compounds for the endocrine therapy of breast cancer – mode of action I: antitumor activity due to the reduction of the endogenous estrogen level, *Arch. Pharm. Pharm. Med. Chem.* **2004**, *337*, 335-348

128) Schertl, S., Hartmann, R.W., Batzl-Hartmann, C., Bernhardt, G., Spruß, T., Beckenlehner, K., Koch, M., Krauser, R., Schlemmer, R., Gust, R., Schönenberger, H., [1,2-Bis(2,6-difluoro-3-hydroxyphenyl)ethylenediamine]platinum(II) complexes, compounds for the endocrine therapy of breast cancer – mode of action II: contribution of drug inactivation, cellular drug uptake and sterical factors in the drug-target interaction to the antitumor activity, *Arch. Pharm. Pharm. Med. Chem.* **2004**, *337*, 349-359

129) Kang, M.J., Mathur, S., Hartmann, R.W., Quantitative analysis of 5α-reductase inhibitors in DU145 cells using matrix-assisted laser desorption/ionisation time-of-flight mass spectrometry and high-performance liquid chromatography/tandem mass spectrometry, *J. Mass Spectrometry* **2004**, *39*, 762-769

130) Hutter, M.C., Hartmann, R.W., QSAR of human steroid 5α-reductase inhibitors: Where are the differences between isoenzyme type 1 and 2?, *QSAR Comb. Sci.* **2004**, *23*, 406-415

131) Lisurek, M., Kang, M.J., Hartmann, R.W., Bernhardt, R., Identification of Monohydroxy progesterones produced by CYP106A2 using comparative HPLC and electrospray ionisation collision-induced dissociation mass spectrometry, *Biochem. Biophys. Res. Comm.* **2004**, *319*, 677-682

132) Voets, M., Müller-Vieira, U., Marchais-Oberwinkler, S., Hartmann, R.W., Synthesis of amidinohydrazones and evaluation of their inhibitory effect towards aldosterone synthase (CYP11B2) and the formation of selected steroids, *Arch. Pharm. Pharm. Med. Chem.* **2004**, *337*, 411-416

133) Kang, M.J., Lisurek, M., Bernhardt, R., Hartmann R.W., Use of high-performance liquid chromatography/electrospray ionization collision-induced dissociation mass spectrometry for structural identification of monohydroxylated progesterones, *Rapid Comm. in Mass Spec.* **2004**, *18*, 2795-2800

134) Leonetti, F., Favia, A., Rao, A., Aliano, R., Paluszcak, A., Hartmann, R.W., Carotti, A., Design, synthesis and 3D QSAR of novel potent and selective aromatase inhibitors, *J. Med. Chem.* **2004**, *47*, 6792-6803

135) Lézé, M.P., Le Borgne, M., Marchand, P., Loquet, D., Kogler, M., Le Baut, G., Palusczak, A., Hartmann, R.W., 2-and 3-[(aryl)(azolyl)methyl]indoles as potential non-steroidal aromatase inhibitors, *J. Enz. Inhib. Med. Chem.* **2004**, *19*, 549-557

136) Bild, T., Jose, J., Hartmann, R.W., Discovery of inhibitors of the MCF-7 tumor cell adhesion to endothelial cells and investigation on their mode of action, *Arch. Pharm. Pharm. Med. Chem.* **2004**, *337*, 687-694.

137) Mathur, S., Park, J.D., Kim, D.H., Hartmann, R.W., A method for screening enzyme inhibitors using size exclusion chromatography and ESI-LC-MS/MS, *J. Biomol. Screening* **2005**, *10*, 30-35

138) Ulmschneider, S., Müller-Vieira, U., Mitrenga, M., Hartmann, R.W., Marchais-Oberwinkler, S., Klein, C.D.P., Bureik, M., Bernhardt, R., Antes, I., Lengauer, T., Synthesis and evaluation of imidazolylmethylenetetrahydronaphthalenes and imidazolylmethyleneindanes: potent inhibitors of aldosterone synthase, *J. Med. Chem.* **2005**, *48*, 1796-1805

139) Haidar, S., Hartmann, R.W., Enzyme inhibitor examples for the treatment of prostate tumor. In: Smith, H.J., Simons, C. (Hrsg.) Enzymes and their inhibition: drug development, *CRC Press* **2005**, 241-253

140) Streiber, M., Picard, F., Scherer, C., Seidel, S.B., Hartmann, R.W., Methyl esters of *N*- (dicyclohexyl)acetyl-piperidine-4-(benzylidene-4-carboxylic acids) as drugs and prodrugs: a new strategy for dual inhibition of 5α-reductase type 1 and type 2, *J. Pharm. Sci.* **2005**, *94*, 473-480

141) Ulmschneider, S., Müller-Vieira, U., Klein, C.D.P., Antes, I., Lengauer, T., Hartmann, R.W., Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitors of aldosterone synthase, *J. Med. Chem.* **2005**, *48*, 1563-1575, Add. and Corr. *J. Med.Chem.* **2005**, *48*, 4489-4490

142) Panter, B., Jose, J., Hartmann, R.W., 5 α-reductase in human embryonic kidney cell line HEK293: evidence for type II enzyme expression and activity, *Mol. Cell. Biochem.* **2005**, *270*, 201-208

143) Jindal, D.P., Bedi V., Jit, B., Karkra, N., Guleria, S., Bansal, R., Palusczak, A., Hartmann, R.W., Synthesis and study of some new N-substituted imide derivatives as potential anticancer agents, *Il Farmaco* **2005**, *60*, 283-290.

144) Angotti, M., Hartmann R.W., Kirby, A.J., Simons, C., Nicholls, P.J., Sewell R.D.E., Smith, H.J., Effect of 2-(4-aminophenylmethyl)-6-hydroxy-3,4-dihydronaphthalen-1(2*H*)-one on all-trans and 13-cis-retinoic acid levels in plasma quantified by high performance liquid chromatography coupled to tandem mass spectrometry, *J. Enz. Inhib. Med. Chem.* **2005**, *20*, 219-226

145) Müller-Vieira, U., Angotti, M., Hartmann, R.W., The adrenocortical tumor cell line NCI-H295R as an in vitro screening system for the evaluation of CAP11B2 (aldosterone synthase) CYP11B2 (steroid-11β-hydroxylase) inhibitors, *J. Steroid Biochem. Mol. Biol.* **2005**, *96*, 259-270

146) Voets, M., Antes, I., Scherer, C., Müller-Vieira, U., Biemel, K., Barassin, C., Marchais-Oberwinkler, S., Hartmann, R.W., Heteroaryl substituted naphthalenes and structurally modified derivatives: selective inhibitors of CYP11B2 for the treatment of congestive heart failure and myocardial fibrosis, *J. Med. Chem.* **2005**, *48*, 6632-6642

147) Cavalli, A., Bisi, A., Bertucci, C., Rosini, C., Paluszcak, A., Gobbi, S., Giorgio, E., Rampa, A., Belluti, F., Piazzi, L., Valenti, P., Hartmann, R.W., Recanatini, M., Enantioselective nonsteroidal aromatase inhibitors identified through a multi disciplinary medicinal chemistry approach, *J. Med. Chem.* **2005,** *48,* 7282-7289

148) Logé, C., Le Borgne, M., Marchand, P., Robert, Le Baut, G., J.-M., Palzer, M., Hartmann, R.W., Three-dimensional model of cytochrome P450 human aromatase and docking studies in to the active site, *J. Enz. Inhib. Med. Chem.* **2005**, *20*, 581-585

149) Ulmschneider, S., Negri, M., Voets, M., Hartmann, R.W., Development and evaluation of a pharmacophore model for inhibitors of aldosterone synthase (CYP11B2), *Bioorg. Med. Chem. Lett.* **2006**, *16*, 25-30

150) Lézé, M.P., Le Borgne, M., Pinson, P., Palusczak, A., Duflos, M., Le Baut, G., Hartmann, R.W., Synthesis and biological evaluation of 5-[(aryl)(1*H*-imidazol-1-yl)methyl]-1*H*-indoles: Potent and selective aromatase inhibitors, *Bioorg. Med. Chem. Lett.* **2006**, *16*, 1134-1137

151) Salem, O.I.A., Frotscher, M., Scherer, C., Neugebauer, Biemel, K., S., Streiber, M., Maas, R., Hartmann, R.W., Novel 5 α-reductase inhibitors: Synthesis, structure-activity studies and pharmacokinetic profile of phenoxybenzoylphenyl acetic acids, *J. Med. Chem.* **2006**, *49*, 748-759.

152) Voets, M., Antes, I., Scherer, C., Müller-Vieira, U., Biemel, K., Marchais-Oberwinkler, S., Hartmann, R.W., Synthesis and evaluation of heteroaryl-substituted dihydronaphthalenes and indenes: Potent and selective inhibitors of aldosterone synthase (CYP11B2) for the treatment of congestive heart failure and myocardial fibrosis, *J. Med. Chem.* **2006**, *49*, 2222 -2231

153) Schuster, D., Laggner, C., Steindl, T.M., Palusczak, A., Hartmann, R.W., Langer, T.;

Pharmacophore modeling and In Silico screening for new P450 19 (Aromatase) Inhibitors, *J. Chem. Inf. Model.* **2006**, *46*, 1301-1311

154) Görlitzer, K., Bonnekessel, Ch., Jones, P.G., Palusczak, A., Hartmann, R.W., Exemestan-Derivate – Synthese und Prüfung auf Aromatase-Hemmung, *Pharmazie* **2006**, *61*, 575-582

155) Gobbi, S., Cavalli, A., Rampa, A., Belluti, F., Piazzi, L., Paluszcak, A., Hartmann, R.W., Recanatini, M., Bisi, A., Lead optimization providing a series of flavone derivatives as potent nonsteroidal inhibitors of the cytochrome P450 aromatase enzyme, *J. Med. Chem.* **2006,** *49*, 4777-4780

156) Jazbutyte, V., Hu, K., Kruchten, P., Bey, E., Maier, S., Fritzemeier K.-H., Prelle, K., Hegele-Hartung, C., Hartmann R.W., Neyses, L., Ertl, G., Pelzer, T., Ageing reduces the efficacy of estrogen substitution to attenuate cardiac hypertrophy in female SHR, *Hypertension* **2006**, *48*, 579-586

157) Engel, M., Hindie, V., Lopez-Garcia, L.A., Stroba, A., Schaeffer, F., Adrian, I., Imig, J., Idrissova, L., Nastainczyk, W., Zeuzem, S., Alzari, P.M., Hartmann, R.W., Piiper, A. and Biondi, R.M., Allosteric activation of protein kinase PDK1 with low molecular weight compounds, *EMBO J*. **2006**, *23*, 5469-5480

158) Drăgan, C.A., Hartmann, R.W., Bureik, M., A fission yeast based test system for the determination of IC_{50} values of anti prostate tumor drugs acting on CYP21, *J. Enz. Inhib.Med.Chem.* **2006,** *21,* 547-556

159) Schertl, S., Hartmann, R.W., Batzl-Hartmann, C., Spruß, T., Maucher, A., von Angerer, E., Schiller, C.D., Schneider, M.R., Gust, R., Schönenberger, H., Platinum(II) complexes interfering with testicular steroid biosynthesis: drugs for the therapy of advanced or recurrent prostate cancers? Preclinical studies, *Cancer Res. Clin. Oncol.* **2007**, *133*, 153-167

160) Gobbi, S., Cavalli, A., Negri, M., Schewe K., Belluti F., Piazzi L., Hartmann, R. W., Recanatini M., Bisi A., Imidazolylmethylbenzophenones as highly potent aromatase inhibitors, *J. Med. Chem*. **2007**, *50*, 3420-3422

161) McCarthy, A., Hartmann R.W., Abell, A., Evaluation of 4'-substituted bicyclic pyridones as non-steroidal inhibitors of steroid 5α-reductase, *Bioorg. Med. Chem. Lett.* **2007,** *17*, 3603-3607

162) Neugebauer, A., Hartmann, R.W., Klein, C.D.P., Prediction of protein-protein interaction inhibitors by chemoinformatics and machine learning methods, *J. Med. Chem.* **2007***, 19,* 4665-4668

163) Le Borgne, M., Marchand, P., Nourrisson, M.R., Loquet, D., Palzer, M., Le Baut, G., Hartmann, R.W., Synthesis and biological evaluation of 3-(αazolylmethyl)-1H-indoles and 3-(azolylbenzyl)-1H-indoles as selective aromatase inhibitors, *J. Enz. Inhib. Med. Chem.* **2007,** *22*, 667-676

164) Pinto-Bazurco Mendieta, M. A.E., Negri, M., Jagusch, C., Hille, U.E., Müller-Vieira, U., Schmidt, D., Hansen, K., Hartmann, R.W., Synthesis, biological evaluation and molecular modeling studies of novel ACD- and ABD-ring steroidomimetics as inhibitors of CYP17, *Bioorg. Med. Chem. Lett.* **2008,** *18*, 267-273

165) Jagusch, C., Negri, M., Hille, U.E., Hu, Q., Bartels, M., Jahn-Hoffmann, K., Pinto-Bazurco Mendieta M.A.E., Rodenwaldt, B., Müller-Vieira, U., Schmidt, D., Lauterbach, T., Recanatinti, M., Cavalli, A., Hartmann, R.W., Synthesis, biological evaluation and molecular modeling studies of methyleneimidazole substituted biaryls

as inhibitors of human 17 α-hydroxylase-17,20-lyase (CYP17) - Part I: heterocyclic modifications of the core structure, *Bioorg. Med. Chem.* **2008**, *16*, 1992-2010

166) Frotscher, M., Ziegler, E., Marchais-Oberwinkler, S., Kruchten, P., Neugebauer, A., Fetzer, L., Scherer, C., Müller-Vieira, U., Messinger, J., Thole, H., Hartmann, R.W., Design, synthesis and biological evaluation of (hydroxyphenyl)naphthalene and quinoline derivatives: Potent, selective and nonsteroidal inhibitors of 17β-hydroxysteroid dehydrogenase type 1 (17β-HSD1) for the treatment of estrogen-dependent diseases, *J. Med. Chem.* **2008**, *51,* 2158-2169

167) Holzer, M., Ziegler, S., Kronenberger, B., Klein, C.D.P., Hartmann, R.W., Microwave assisted syntheses of amino acid ester substituted benzoic acid amides: Potential inhibitors of human CD81-receptor HCV-E2 interaction, *The Open Med. Chem .J.* **2008***, 2,* 21-25

168) Holzer, M., Ziegler, S., Albrecht, B., Kronenberger B., Kaul, A., Bartenschlager R., Kattner, L., Klein, C.D., Hartmann, R.W., Identification of terfenadine as an inhibitor of human CD81-receptor HCV-E2 interaction, synthesis and structure optimization, *Molecules* **2008***, 13,* 1081-1110

169) Hartmann, R.W., Müller-Vieira, U., Ulmschneider, S., Voets, M., Discovery of potent and selective inhibitors of human aldosterone synthase (CYP11B2) – a new target for the treatment of congestive heart failure and myocardial fibrosis: A review, In: *Medicinal Chemistry: Chemical and Molecular Aspects of Drug Design and Action, Taylor and Francis/ CRC Publishing Company* **2008***, 12,* 165-175

170) Bey, E., Marchais-Oberwinkler, Kruchten, P., S., Frotscher, M., Werth, R., Oster, A., Algul, Ö., Neugebauer, A., Hartmann, R.W., Design, synthesis and biological evaluation of bis(hydroxyphenyl) azoles as potent and selective non steroidal inhibitors of 17ß-hydroxysteroid dehydrogenase type 1 (17ß-HSD1) for the treatment of estrogen dependent diseases, *Bioorg. Med. Chem.* **2008,** *16,* 6423-6435

171) Holzer, M., Ziegler, S., Neugebauer, A., Kronenberger, B., Klein, C.D.P., Hartmann, R.W., Structural modification of salicylates: inhibitors of human CD81-receptor HCV-E2 interaction, *Arch. Pharm. Chem. Life Sci.* **2008***, 341,* 478-484

172) Marchais-Oberwinkler, S. , Kruchten, P., Frotscher M., Ziegler, E., Neugebauer, Bhoga, U., Bey, E., Müller-Vieira, U., Messinger, J., Thole, H., Hartmann, R.W., Substituted 6-phenyl-2-naphthols. Potent and selective nonsteroidal inhibitors of 17ß-hydroxysteroid dehydrogenase type 1 (17 ß-HSD1): Design, synthesis, biological evaluation and pharmacokinetics, *J. Med .Chem.* **2008***, 51,* 4685-4698

173) Heim, R., Lucas, S., Grombein, C.M., Ries, C., Schewe, K.E., Negri, M., Müller-Vieira, U., Hu, Q Hartmann, R.W., Overcoming undesirable CYP1A2 potency of pyridylnaphthalene type aldosterone synthase inhibitors: Influence of heteroaryl substitution on potency and selectivity, *J. Med. Chem.* **2008***, 51,* 5064-5074

174) Hu, Q., Negri, M., Jahn-Hoffmann, K., Zhuang,Y., Olgen, S., Bartels, M., Müller- Vieira, U., Lauterbach, T., Hartmann, R.W., Synthesis, biological evaluation and molecular modelling studies of methylene imidazole substituted biaryls as inhibitors of human 17α-hydroxylase-17, 20-lyase (CYP17) – Part II: Core rigidification and influence of substituents at the methylene bridge, *Bioorg. Med. Chem.* **2008***, 16,* 7715-7727

175) Pinto-Bazurco Mendieta M., Negri, M., Jagusch, C., Müller-Vieira, U., Lauterbach T., Hartmann, R.W., Synthesis, biological evaluation and molecular modeling of abiraterone analogs: Novel CYP17 inhibitors for the treatment of prostate cancer, *J. Med. Chem.* **2008***, 51,* 5009-5018

176) Lucas, S., Heim, R., Negri, M., Antes, I., Ries, C., Schewe, K., Bisi, A., Gobbi, S., Hartmann, R.W., Novel aldosterone synthase inhibitors with extended carbocyclic skeleton by a combined ligand-based and structure-based drug design approach, *J. Med. Chem.* **2008***, 51,* 6138-6149

177) Castellano, S., Stefancich, G., Ragno, R., Schewe, K., Santoriello M., Caroli, A., Hartmann, R.W., Sbardella, G., CYP19 (Aromatase): Exploring the scaffold flexibility for novel selective inhibitors, *Bioorg. Med. Chem.* **2008***, 18,* 8349-8358.

178) Pinto-Bazurco Mendieta M., Negri, M., Hu, Q., Hille, U., Jagusch, C., Jahn-Hoffmann, K., Müller-Vieira, U., Jahn-Hoffmann, K., Schmidt, D., Lauterbach, T., Hartmann, R.W., CYP17 inhibitors. Annulations of additional rings in methyleneimidazole substituted biphenyls: Synthesis, biological evaluation and modelling, *Arch.Pharm. Chem. Life Sci.* **2008**, *341,* 597-609

179) Léze, M.-P., Palusczak, A., Hartmann, R.W., Le Borge M., Synthesis of 6- or 4-functionalized indoles via a reductive cyclization approach and evaluation as aromatase inhibitors, *Bioorg. Med. Chem.* **2008**, *18,* 4713- 4715

180) Bey, E., Marchais-Oberwinkler, S., Werth, R., Negri, M., Al-Soud, Y., Kruchten, P., Oster A., Frotscher, M., Birk, B., Hartmann, R.W., Design, synthesis, biological evaluation and pharmacokinetics of bis(hydroxyphenyl)substituted azoles, thiophenes, benzenes and aza-benzenes as potent and selective non-steroidal inhibitors of 17 ß -hydroxysteroid dehydrogenase type 1 (17ß-HSD1), *J. Med. Chem.* **2008***, 51,* 6725-6739

181) Gaube, F., Wölfl, S., Pusch, L., Werner, U., Kroll, T.C., Schrenk, D., Hartmann R.W., Hamburger M., Effects of Leuzea carthamoides on human breast adenocarcinoma MCF-7 cells determined by gene expression profiling and functional assays, *Planta Medica* **2008,** *74,* 1701-1708

182) Lucas, S., Heim, Ries, C., Schewe, K., Birk B., Hartmann, R.W., In vivo active aldosterone synthase inhibitors with improved selectivity: Lead optimization providing a series of pyridine substituted 3,4-dihydro-1H-quinolin-2-one derivates, *J. Med. Chem.* **2008**, *51,* 8077-8087

183) Marchais-Oberwinkler, S., Frotscher, M., Ziegler, E., Werth, R., Kruchten, P., Messinger, J., Thole, H., Hartmann, R.W., Structure-activity study in the class of 6-(3'-hydroxyphenyl)naphthalenes leading to an optimization of a pharmacophore model for 17beta-hydroxysteroid dehydrogenase type1 (17beta-HSD1) inhibitors, *Mol. Cell. Endocrinol.* **2009,** *301,* 205-211

184) Kruchten, P., Werth, R., Marchais-Oberwinkler, S., Frotscher, M., Hartmann, R.W., Development of a biological screening system fort the evaluation of highly active and selective 17beta-HSD1-inhibitors as potential therapeutic agens, *Mol. Cell. Endocrinol.* **2009***, 301,* 154-157

185) Al-Soud, Y. A., Bey, E., Oster A., Marchais-Oberwinkler, S.,Werth, R., Kruchten, P., Frotscher, M., Hartmann, R.W., The role of the heterocycle in bis(hydroxyphenyl)triazoles for inhibition of 17beta-hydroxysteroid dehydrogenase (17beta- HSD) type 1 and type 2, *Mol. Cell. Endocrinol.* **2009,** *301,* 212-215

186) Kruchten, P., Werth, R., Bey, E., Oster, A., Marchais-Oberwinkler, S., Frotscher, M.,

Hartmann, R.W., Selective inhibition of 17beta-hydroxysteroid dehydrogenase type 1 (17betaHSD1) reduces estrogen responsive cell growth of T47-D breast cancer cells, *J. Steroid Biochem. Mol. Biol.* **2009,** *114,* 200-206

187) Hille, U., Hu Q., Bartels, M., Müller-Vieira, U., Schmidt, D., Lauterbach, T., Hartmann, R.W., Novel CYP17 inhibitors: Synthesis, biological evaluation, structure-activity relationships and modelling of methoxy-and hydroxy-substituted methyleneimidazolyl biphenyls, *Eur. J. Med. Chem.* **2009,** *44*, 2765-2775

188) Ries, C., Lucas, S., Heim, R., Birk, B., Hartmann, R.W., Selective aldosterone synthase inhibitors reduce aldosterone formation in vitro and in vivo, *J. Steroid Biochem. Mol. Biol.* **2009,** *116,* 121-126

189) Stroba, A., Schaeffer, F., Hindie, V., Lopez-Garcia, L., Adrian, I., Fröhner, W., Hartmann, R.W., Biondi, R.M., Engel, M., 3,5-Diphenylpent-2-enoic acids as allosteric activators of the protein kinase PDK1: Structure-activity relationships and thermodynamic characterisation of binding as paradigms for PIF-binding pocket-targeting compounds, *J. Med. Chem.* **2009,** *15*, 4683-4693.

190) Ziegler, S., Kronenberger B., Albrecht B. A.-M., Kaul A., Gamer A.-L., Klein, C.D., Hartmann, R.W., Development and evaluation of a FACS-based medium throughput assay for HCV entry inhibitors, *J. Biomol. Screening* **2009,** *6,* 620-626

191) Kruchten, P., Werth, R., Marchais-Oberwinkler, S., Bey, E., Ziegler E., Oster A. Frotscher, M., Hartmann, R.W., Development of biological assays for the identification of selective inhibitors of estradiol formation from estrone in rat liver preparations, *Comptes Rendus Chimie* **2009,** *12,* 1110-1116

192) Hille, U., Hu, Q., Pinto-Bazurco Mendieta, M., Bartels, M., Vock, C.A., Lauterbach, T., Hartmann, R.W., Steroidogenic cytochrome P450 (CYP) enzymes as drug targets: Combining substructures of known CYP inhibitors leads to compounds with different inhibitory profile, *Comptes Rendus Chimie* **2009,** *12,* 1117-1126

193) Bey, E., Marchais-Oberwinkler, S., Negri, M., Kruchten, P., Oster A., Klein, T., Spadaro. A., Werth, R., Frotscher, M., Birk, B., Hartmann, R.W., New insights into the SAR and binding modes of bis(hydroxyphenyl)thiophenes and benzenes: Influence of additional substituents on 17 ß-hydroxysteroid dehydrogenase type 1 (17ß-HSD1) inhibitory activity and selectivity, *J. Med. Chem.* **2009,** *52,* 6724-6743

194) Hu, Q., Negri, M., Olgen, S., Hartmann, R.W., The role of fluorine Substitution in biphenyl methylene imidazole type CYP17 inhibitors for the treatment of prostate carcinoma, *ChemMedChem* **2010,** *5,* 899-910

195) Oster, A., Klein, T., Werth, R., Kruchten, P., Bey, E., Negri, M., Marchais-Oberwinkler, S., Frotscher, M., Hartmann, R.W., Novel estrone mimetics with high 17β-HSD1 inhibitory activity, *Bioorg. Med. Chem.* **2010,** *18,* 3494-3505

196) Haller, F., Moman, E., Hartmann, R.W., Adamski, J., Mindnich, R., Molecular framework of steroid/retinoid discrimination in 17beta-hydroxysteroid dehydrogenase type 1 and photoreceptor-associated retinol dehydrogenase, *J. Mol. Biol.* **2010,** *399,* 255-267

197) Bansal, R. Guleria, S., Ries, C., Hartmann R.W., Synthesis and antineoplastic activity of *O*-alkylated derivatives of 7-hydroximinoandrost-5-ene steroids, *Arch. Pharm. Chem. Life Sci.* **2010,** *343,* 377-383

198) Negri, M., Recanatini, M., Hartmann, R.W., Insights in 17β-HSD1 enzyme kinetics and ligand binding by dynamic motion investigation, *PLoS One* **2010***, 5,* e12026

199) Welker, M.-W., Von Wagner, M., Ochs, D. Zimmer, V., Hofmann, W.P., Piiper, A., Hartmann, R.W., Herrmann, E., Zeuzem, S., Kronenberger, B., Influence of amantadine on CD81 expression on lymphocytes in chronic hepatitis C, *Digestive and Liver Disease* **2010***, 42*, 735-740

200) Hu, Q., Jagusch, C., Hille, U., Haupenthal, J., Hartmann, R.W., Replacement of imidazolyl by pyridyl in biphenylmethylenes results in selective CYP17 and dual CYP17/CYP11B1 inhibitors for the treatment of prostate cancer, *J. Med. Chem.* **2010,** *53*, 5749-5758

201) Gobbi, S., Zimmer, C., Belluti, F., Rampa, A., Hartmann, R.W., Recanatini, M., Bisi, A., Novel highly potent and selective nonsteroidal aromatase inhibitors: Synthesis, biological evaluation and strucure -activity relationships investigation, *J. Med. Chem.* **2010,** *53*, 5347-5351

202) Hu, Q., Yin, L., Jagusch, C., Hille, U.E., Hartmann, R.W., Isopropylidene substitution increases activity and selectivity of biphenylmethylene 4-pyridine type CYP17 inhibitors, *J. Med. Chem.* **2010,** *53*, 5049-5053

203) Hahner, S., Stürmer, A., Fassnacht, M., Hartmann, R.W., Schewe, K., Cochran S., Zink M., Schirbel A., Allolio B., Etomidate unmasks intraadrenal regulation of steroidogensis and proliferation in adrenal cortical cell lines, *Horm. Metab. Res.* **2010**, *42*, 528-534

204) Reum, N., Fink-Straube, C., Klein, T., Hartmann, R.W., Lehr, C.-M., Schneider, M., Multilayer coating of gold nanoparticles with drug-polymer coadsorbates, *Langmuir* **2010***, 26*, 16901-16908

205) Oster, A., Hinsberger, S., Werth R., Marchaise-Oberwinkler, S., Frotscher, M., Hartmann, R.W., Bicyclic substituted hydroxyphenylmethanones as novel inhibitors 17β-HSD1 for the treatment of estrogen-dependent diseases, *J. Med. Chem.* **2010***, 53,* 8176-8186

206) Heinzerling, L., Hartmann, R.W., Frotscher, M., Neumann, D., Predicting putative inhibitors of 17β-HSD1, *Mol. Inf.* **2010**, *29*, 695-705

207) Zimmer, C., Hafner, M., Zender, M., Amman, D., Hartmann, R.W., Vock, C.A., N-(pyridin-3-yl)benzamides as selective inhibitors of human aldosterone synthase (CYP11B2), *Bioorg. Med. Chem. Lett.* **2011,** *21,* 186-190

208) Wetzel, M., Marchais-Oberwinkler, S. Hartmann, R.W., 17-HSD2 inhibitors for the treatment of osteoporosis: Identification of a promising scaffold, *Bioorg. Med. Chem.* **2011,** *19***,** 807-815

209) Mohammed, A. H., Ba-Bernardi, L., Burkholz T., Schumann, E., Diesel, B., Zapp, J., Kiemer, A.K., Ries, C., Hartmann, R.W., Hosny M., Jacob, C., Facile synthesis of chrysin-derivatives with promising activities as aromatase inhibitors, *NPC* **2011***, 6,* 31-34

210) Marchais-Oberwinkler, S., Wetzel, M., Ziegler, E., Kruchten, P., Werth, R., Henn, C., Hartmann, R.W., Frotscher, M., New drug-like hydroxyphenylnaphthol steroidomimetics as potent and selective 17β-HSD1 inhibitors for the treatment of

estrogen-dependent diseases, *J. Med. Chem.* **2011,** *54*, 534-547

211) Hille, U. E., Zimmer, C., Vock, C.A., Hartmann, R.W., First selective CYP11B1 inhibitors for the treatment of cortisol dependent diseases, ACS *Med. Chem. Lett.* **2011,** *2,* 2-6

212) Oster, A., Klein, T., Henn, C., Werth, R., Marchais-Oberwinkler, S., Frotscher, M., Hartmann, R.W., Bicyclic substituted hydroxyphenylmethanone type inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1): The role of the bicyclic moiety, *ChemMedChem.* **2011,** *3,* 476-487

213) Yadav, M.R., Sabale, P.M., Giridhar, R., Zimmer, C., Haupenthal, J., Hartmann, R.W., Synthesis of some novel androstanes as potential aromatase inhibitors, *Steroids* **2011,** *76,* 464-470

214) Bansal, R. Guleria, S., Thota, S., Hartmann, R.W., Zimmer, C., Synthesis and biological evaluation of 16*E*-arylidenosteroids as cytotoxic and anti-aromatase agents, *Chem. Pharm. Bull.* **2011,** *59,* 327-311

215) Stefanachi, A, Favia, A.D., Nicolotti, O., Leonetti, F., Pisani, L., Catto, M., Zimmer, C., Hartmann, R.W., Carotti, A., Design, synthesis, and biological evaluation of imidazolyl derivatives of 4,7-disubstituted coumarins as aromatase inhibitors selective over 17-α-hydroxylase/C17-20 Lyase, *J. Med. Chem*. **2011**, *54*, 1613-1625

216) Lucas, S., Negri, M., Heim, R., Zimmer, C., Hartmann, R.W., Fine-tuning the selectivity of aldosterone synthase inhibitors: Structure-activity and structure-selectivity insights from studies of heteroaryl substituted 1,2,5,6-tetrahydropyrrolo [3,2,1-*ij*] quinolin-4-one derivatives, *J. Med. Chem.* **2011,** *54,* 2307-2319

217) Pistorius, D., Ullrich, A., Lucas, S., Hartmann, R.W., Kazmaier, U., Müller, R., Biosynthesis of 2-alkyl-4(1*H*)-quinolones in *Pseudomonas aeruginosa*: Potential for therapeutic interference with pathogenicity, *ChemBioChem* **2011**, *12*, 850-853

218) Xu, K., Wetzel, M., Hartmann R.W., Marchais-Oberwinkler, S., Synthesis and biological evaluation of spiro-δ-lactones as inhibitors of 17β-hydroxysteroid dehydrogenase type 2 (17β-HSD2), *Lett. Drug Des. Discov.* **2011,** *8*, 406-421

219) Marchais-Oberwinkler, S., Henn, C., Möller, G., Klein, T., Negri, M., Oster, A., Spadaro, A., Werth, R., Wetzel, M., Xu, K., Frotscher, M., Hartmann, R.W., Adamski, J., 17β-Hydroxysteroid dehydrogenases (17β-HSDs) as therapeutic targets: Protein structures, functions, and recent progress in inhibitor development, *J. Steroid Biochem. Mol. Biol*. **2011,** *125,* 66-82

220) Klein, T., Henn, C., Negri, M., Frotscher, M., Structural basis for species specific inhibition of 17β-hydroxysteroid dehydrogenase typ 1(17β-HSD1): Computational study and biological validation, *PLoS One* **2011,** *6,* e22990

221) Bansal, R., Narang, G., Ries, C., Hartmann, R.W., Synthesis of some imidazolyl substituted 2-benzylidene indanone derivatives as potent aromatase inhibitors for breast cancer therapy, *Med. Chem. Res.* **2011,** *20***,** 661-669

222) Welker, M.-W., Welsch, C., Ochs, D., Hofmann W.P., Herrmann, E., Piiper, A., Hartmann, R.W., Zeuzem, S., Sarrazin, C., Kronenberger, B., Comparison of Envelope 2 CD81 binding regions in PBMC-derived versus serum-derived hepatitis C virus isolates: Higher conservation in CD81 region 2 in PBMC isolates, *J. Viral Hepat.* **2011,** *18,* 181-192

223) Hille, U.E., Zimmer, C., Haupenthal, J., Hartmann, R.W., Optimization of the first

selective steroid-11β-hydroxylase (CYP11B1) inhibitors for the treatment of cortisol dependent diseases, *Med. Chem. Lett.* **2011,** *2*, 559-564

224) Negri, M., Recanatini, M., Hartmann, R.W., Computational investigation of the binding mode of bis(hydroxylphenyl)arenes in 17β-HSD1: molecular dynamics simulations, free energy calculations, and molecular electrostatic potential maps, *J Comput Aided Mol Des***. 2011,** *25,* 795-811

225) Xu, K., Yaseen, A. S., Wetzel, M., Hartmann, R. W., Marchais-Oberwinkler, S., Triazole ring-opening leads to the discovery of potent nonsteroidal 17β-hydroxysteroid dehydrogenase type 2 inhibitors, *Eur*. *J. Med. Chem.* **2011***, 46*, 5978-5990

226) Wetzel, M., Marchais-Oberwinkler, S., Perspicace, E., Möller, G., Adamski, J., Hartmann, R.W., Introduction of an electron withdrawing group on the hydroxyphenylnapththol scaffold improves the potency of 17β-hydroxysteroid dehydrogenase type 2 (17β-HSD2) inhibitors, *J. Med. Chem* **2011***, 54,* 7547-7557

227) Al-Soud Y. A., Heydel, M., Hartmann, R.W., Design and synthesis of 1,3,5-trisubstituted 1,2,4-triazoles as CYP enzyme inhibitors**,** *Tetrahedron Lett.* **2011***, 52,* 6372-6375

228) Yadav, M.R., Sabale, P.M., Giridhar, R., Baria, D., Zimmer, C., Hartmann, R.W., Synthesis and preliminary screening of novel A- and D-ring modified steroids as aromatase inhibitors, *Lett. Drug. Des. Discov.,* **2011***, 8*, 943-950

229) Wetzel, M., Gargano, E. M., Hinsberger, S., Marchais-Oberwinkler, S., Hartmann, R.W., Discovery of a new class of bicyclic substituted hydroxyphenylmethanones as 17β-hydroxysteroid dehydrogenase type 2 (17β-HSD2) inhibitors for the treatment of osteoporosis, *Eur. J. Med. Chem.*, **2012,** *47*, 1-17

230) Spadaro, A., Negri, M., Marchais-Oberwinkler. S., Bey, E., Frotscher, M.,

Hydroxybenzothiazoles as new nonsteroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1), *PLoS One,* **2012**, *7*, e29252

231) Henn, C., Einspanier, A., Oberwinkler-Marchais, S., Frotscher, M., Hartmann, R.W., Lead optimization of 17β-HSD1 inhibitors of the (hydroxyphenyl)naphthol sulfonamide type for the treatment of endometriosis, *J. Med. Chem.*, **2012**, *55*, 3307-3318

232) Lu, C., Kirsch, B., Zimmer, C., De Jong, J.C., Maurer, C., Müsken, M., Häussler, S., Steinbach, A., Hartmann, R.W., Discovery of antagonists of PqsR, a key player in 2-Alkyl-4-quinolone-dependent *Quorum Sensing* in *Pseudomonas aeruginosa, Chem. Biol.* **2012**, *19*, 381-390

233) Spadaro, A., Frotscher, M., Hartmann, R.W., Optimization of hydroxybenzothiazoles as novel potent and selective inhibitors of 17β-HSD1, *J. Med. Chem*. **2012**, *55*, 2469-2473

234) Bansal, R., Guleria, S., Thota, S., Bodhankar, s.L., Moreshwar, R.P. Zimmer, C., Hartmann, R.W.,L Harvey, A., Design, synthesis and evaluation of novel 16-imidazolyl substituted steroidal derivatives possessing potent diversified pharmacological properties**,** *Steroids*, **2012,** *77,* 621-629

235) Yadav, M.R., Sabale, M.P., Giridhar, R., Zimmer, C., Hartmann, R.W., Steroidal carbonitriles as potential aromatase inhibitors, *Steroids*, **2012**, *77*, 850–857

236) Haidar S., Boettcher, S., Al Maridini M.A., Hartmann R.W., Purity of five generic bulk montelukast sodium using liquid chromatography/mass spectrometry, *Int J Pharm Pharm,* **2012**. *4*, 686-690

237) Henn, C., Boettcher, S., Steinbach, A., Hartmann, R.W., Catalytic enzyme activity on a biosensor chip: Combination of surface plasmon resonance and mass spectrometry, *Anal. Biochem.* **2012**, *428* , 28-30

238) Yin, L., Lucas, S. Maurer, F., Kazmaier, U., Hu, Q., Hartmann, R.W., Novel imidazol-1-ylethyl substituted 1,2,5,6-Tetrahydro-pyrrolo[3,2,1-ij]quinolin-4-ones as potent and selective CYP11B1 inhibitors for the treatment of cushing's syndrome, *J. Med. Chem.***2012**, *55*, 6629-6633

239) Aggarwal, S., Thareja, S., Bhardwaj, T.R., Haupenthal, J., Hartmann, R.W., Kumar, M., Synthesis and biological evaluation of novel unsaturated carboxysteroids as human 5α-reductase inhibitors: A legitimate approach, *Eur. J. Med. Chem.* **2012**, *54*, 728-39

240) Al-Soud, Y. A., Marchais-Oberwinkler, S., Frotscher, M., Hartmann, R.W., Synthesis and biological evaluation of phenyl substituted *1H*-1,2,4-triazoles as non-steroidal inhibitors of 17β-hydroxysteroid dehydrogenase type 2, *Archiv der Pharmazie,* **2012**, *345*, 610-621

241) Hu, Q., Yin, L., Hartmann, R.W., Selective dual inhibitors of CYP19 and CYP11B2: Targeting cardiovascular diseases hiding in the shadow of breast cancer, *J. Med. Chem.* ***2012,*** *55,* 7080-7089

242) Abadi, A. H., Abo-Seri, S. Hu, Q., Negri, M., Hartmann, R.W., Synthesis and biological evaluation of imidazolylmethylacridones as cytochrome P-450 enzymes inhibitors, *MedChemComm.* **2012**, *3*, 663-666

243) Klein, T., Henn, C., de Jong J.C., Zimmer, C., Kirsch, B., Maurer, C.K., Pistorius, D., Müller, R., Steinbach, A., Hartmann, R.W., Identification of small-molecule antagonists of the *pseudomonas aeruginosa* transcriptional regulator PqsR: Biophysically guided hit discovery and optimization, *ACS Chem. Biol.* **2012,** *7*, 1496-1501

244) Haupenthal, J., Hüsecken, K., Negri, M., Maurer, C., Hartmann, R.W., Influence of DNA template choice on transcription and inhibition of E. coli RNA polymerase, *Antimicrob. Agents Chemother.* **2012***, 56*, 4536-4539

245) Storz, M., Maurer, C., Zimmer, C., Wagner, N., Brengel, C., de Jong, J., Lucas, S., Müsken, M., Häussler, S., Steinbach, A., Hartmann, R.,Validation of PqsD as anti-biofilm target in Pseudomonas aeruginosa by development of small molecule inhibitors, *J. Am. Chem. Soc.,* **2012***, 134* , 16143-16146

246) Bansal, R., Thota, S., Karkra, N., Minu, M., Zimmer, C., Hartmann, R.W., Synthesis and aromatase inhibitory activity of some new 16*E*-arylidenosteroids, *Bioorg. Chemistry*, **2012**, *45*, 36-40

247) Yin, L., Hu, Q., Hartmann, R.W., 3-Pyridyl substituted aliphatic cycles as CYP11B2 inhibitors: Aromaticity abolishment of the core significantly increased selectivity over CYPA1, *PLoS One,* **2012**, *7*, e48048

248) Bielecki, P., Lukat, P., Hüsecken, K., Dötsch, A., Steinmetz, H. Hartmann, R.W., Müller, R., Häussler, S., Mutation in elongation factor G confers resistance to the antibiotic argyrin in the opportunistic pathogen *Pseudomonas aeruginosa,*

ChemBioChem, **2012***, 13*, 2339-2345

249) Krug, S., Hu, Q., Hartmann, R.W., Hits identified in library screening demonstrate selective CYP17A1 lyase inhibition, *J. Steroid Biochem.Mol. Biol.,* **2012,** *134*, 75-79

250) Bansal, R., Guleria, S., Thota, S., Hartmann, R.W., Zimmer, C., Synthesis of imidazole-derived steroidal hybrids as potent aromatase inhibitors, *Med. Chem. Res.* **2013**, *22*, 692-698

251) El-Gamil, D.S., Ahmed, N.S., Gary, B.D., Piazza, G.A., Engel, M., Hartmann, R.W., Abadi, A.H., Design of novel β-carboline derivatives with pendant 5-bromothienyl and their evaluation as phosphodiesterase-5 inhibitors, *Archiv der Pharmazie,* **2013**, *346*, 23-33

252) Marchais-Oberwinkler, S., Xu, K., Wetzel, M., Perspicace, E., Negri, M., Meyer, A., Odermatt, A., Möller, G., Adamski, J., Hartmann, R. W., Structural optimization of 2,5-thiophene amides as highly potent and selective 17β-hydroxysteroid dehydrogenase type 2 inhibitors for the treatment of osteoporosis, *J. Med. Chem.* **2013,** *56*, 167-81

253) Yin, L., Hu, Q., Hartmann, R. Tetrahydropyrroloquinolinone type dual inhibitors of aromatase/aldosterone synthase as a novel strategy for breast cancer patients with elevated cardiovascular risks**,** *J. Med. Chem.* **2013,** *56,* 460-470

254) Nermin, S. A., Ali, A .H., El-Nashar, S. M., Gary, B. D., Fajardo, A. M., Tinsley, H. N., Piazza, G. A., Negri, M., Abadi, A.H., Exploring the PDE5 H-pocket by ensemble docking and structure-based design and synthesis of novel β-carboline derivatives, *Eur. J. Med. Chem.* **2012,** *57*, 329 – 343.

255) Gobbi, S., Hu, Q., Zimmer, C., Belluti, F., Rampa, A., Hartmann, R.W., Modulation of cytochromes P450 with xanthone-basedmolecules: from aromatase to aldosterone synthase and steroid 11beta-hydroxylase inhibition, *J. Med. Chem.,* **2013**, *56*, 1723-1729

256) Hüsecken, K., Negri, M., Fruth, M., Hartmann, R.W., Haupenthal, J., Peptide-based investigation of the Escherichia coli RNA polymerase σ70:core interface as target site, *ACS Chem. Biol*. **2013,** *8,* 758–766

257) Perspicace, E., Marchais-Oberwinkler. S., Hartmann, R.W. Synthesis and biological evaluation of thieno[3,2-*d*]pyrimidinones, thieno[3,2-*d*]pyrimidines and quinazolinones, conformationally restricted 17β-Hydroxysteroid Dehydrogenase Type 2 (17β-HSD2), *Molecules,* **2013**, *18*, 4487-4509

258) Sahner, H. J., Groh, M., Negri, M., Haupenthal, J., Hartmann, R.W., Novel small molecule inhibitors targeting the “Switch Region” of bacterial RNAP: Structure-based optimization of a virtual screening hit, *Eur. J. Med. Chem.,* **2013**, *65*, 223-231

259) Zhu, W., Groh, M., Haupenthal, J., Hartmann, R.W., A detective story in drug discovery: Elucidation of a screeni ng artifact reveals polymeric carboxylic acids as potent inhibitors of RNA polymerase, *Chem . Eur. J.,* **2013**, *19*, 8397-8400

260) Yin, L., Hu, Q., Hartmann, R.W., Recent progress in pharmaceutical therapies for castration-resistant prostate cancer, *Int. J. Mol. Sci*., **2013**, *14*, 13958-13978

261) Weidel, E., DeJong, J., Brengel, C., Storz, M., Braunshausen, A., Negri, M., Plaza, A., Steinbach, A., Müller, R., Hartmann, R., Structure Optimization of 2-Benzamidobenzoic acids as PqsD inhibitors for Pseudomonas aeruginosa infections and elucidation of binding mode by SPR, STD NMR and molecular docking, *J. Med. Chem.,* **2013**, *56*, 6146−6155

262) Pinto-Bazurco Mendieta, M., Hu, Q., Engel, M., Hartmann, R.W., Highly potent and selective non-steroidal dual inhibitors of CYP17 / CYP11B2 for the treatment of prostate cancer to reduce risks of cardiovascular diseases, *J. Med.Chem.,* **2013**, *56*, 6101−6107

263) Steinbach, A., Maurer, C.K., Henn, C., Weidel, E., Brengel, C., Hartmann, R.W., Negri, M., Molecular basis of HHQ biosynthesis: Molecular dynamics simulations, surface plasmon resonance and enzyme kinetic studies**,** *BMC Biophys,* **2013**, 6:10

264) Berényi, Á., Frotscher, M., Marchais-Oberwinkler, S., Hartmann, R.W., Minorics, R., Ocsovszki, I., Falkay, G., Zupkó, I ., Direct antiproliferative effect of nonsteroidal 17β-hydroxysteroid dehydrogenase type 1 inhibitors *in vitro*, *J. Enzyme Inhib. Med. Chem.,* **2013***, 28*, 695-703

265) Emmerich, J., Hu, Q., Hanke, N., Hartmann, R.W., Cushing's syndrome: development of highly potent and selective CYP11B1 inhibitors of the (pyridylmethyl)pyridine type, *J. Med. Chem*., **2013**, *56*, 6022−6032

266) Maurer, C., Steinbach, A., Hartmann, RW., Development and validation of a UHPLC-MS/MS procedure for quantification of the Pseudomonas Quinolone Signal in bacterial culture after chemical derivatization for characterization of new quorum sensing inhibitors, *J. Pharm. Biomed. Anal.,* **2013***, 86,* 127-134

267) Hamed, M. M., El Ella, D.A.A., Keeton, A.B., Piazza, G.A., Engel, M., Hartmann, R.W., Abadi, A.H., Quinazoline and tetrahydropyridothieno[2,3-d]pyrimidine derivatives as irreversible EGFR tyrosine kinase inhibitors: influence of the position 4 substituent, *MedChemComm*, **2013**, *4* , 1202-1207

268) Hamed, M.M., El Ella, D.A.A., Keeton, A.B., Piazza,G.A., Abadi, A.H., Hartmann, R.W., Engel, M., "6-aryl and heterocycle quinazoline derivatives as potent EGFR inhibitors with improved activity toward Gefitinib-sensitive and -resistant tumor cell lines", *ChemMedChem,* **2013,** *8*, 1495-1504

269) Zender, M., Klein, T., Henn, C., Kirsch, B., Maurer, C.K., Kail, D., Ritter, C., Dolezal, O., Steinbach, A., Hartmann, R.W., Discovery and Biophysical Characterization of 2-Amino-Oxadiazoles as novel Antagonists of PqsR - an important regulator of *Pseudomonas aeruginosa* virulence, *J. Med. Chem.,* **2013**, *56*, 6761−6774

270) Perspicace, E., Giorgio, A., Carotti, A., Marchais-Oberwinkler, S., Hartmann, R.W., Novel N-methylsulfonamide and retro-N-methylsulfonamide derivatives as 17beta-Hydroxysteroid Dehydrogenase Type 2(17beta-HSD2) inhibitors with good ADME-related physicochemical parameters, *Eur. J. Med. Chem.,* **2013***, 69*, 201-215

271) Schaadt, N. S., Steinbach, A., Hartmann, R.W., Helms, V., Rule-based regulatory and metabolic model for Quorum sensing in *P. aeruginosa,* BMC Systems Biology, **2013**, *7*:81

272) Ferlin, M. G., Carta, D., Bortolozzi, R., Ghodsi, R., Chimento, A., Pezzi, V., Moro, S., Hanke, N., Hartmann, R.W., Basso, G., Viola, G., Design, synthesis and SARs of

azolylmethyl-pyrroloquinolines as non steroidal aromatase inhibitors*, J. Med. Chem.,* **2013***, 56***,** 7536-7551

273) Sahner, H.J., Brengel, C., Storz, Groh, M., Plaza, A.P., Negri, M., Müller, R., Hartmann, R.W., Combining in silico and biophysical methods for the development of *Pseudomonas aeruginosa* quorum sensing inhibitors - an alternative approach for structure-based drug design, *J. Med.Chem.,* **2013***, 56,* 8656-8664

274) Hinsberger, S., Groh, M., Negri, M., Haupenthal, J., Hartmann, R., Discovery of novel bacterial RNA polymerase inhibitors: Pharmacophore based virtual screening and hit optimization, *J.Med.Chem.* **2013**, *56*, 8332−8338

275) Abdel-Halim, M., Keeton, A.B., Gurpinar, E., Gary, B.D., Vogel, S. M., Engel, M., A. Piazza, G.P., Frank M. Boeckler, F.M., Hartmann, R.W., Ashraf H. Abadi, A.H. Trisubstituted and tetrasubstituted pyrazolines as a novel class of cell-growth inhibitors in tumor cells with wild type p53, *Bioorg.Med.Chem, **2013,** 21,* 7343–7356

276) Grombein, C.M., Hu, Q., Heim, R., Huch, V., Hartmann, R.W., Unexpected results of a $S_{N,Ar}$- reaction. A novel synthetic approach to 1-arylthio-2-naphthols**,** *Tetrahedron Lett.,* **2013***, 54*, 6615-6618

277) Storz, M.P., Brengel, C., Weidel, E., Hoffmann, M., Hollemeyer, K., Empting, M. Steinbach, A., Müller, R., Hartmann, R.W., Biochemical and biophysical analysis of a chiral PqsD inhibitor revealing tight-binding behavior and enantiomers with contrary thermodynamic signatures, *ACS Chem. Biol*., **2013,** *8*, 2794-2801

278) Elgaher, W.A.M., Fruth, M., Groh, M., Hartmann, R.W., Expanding the scaffold for bacterial RNA polymerase inhibitors: Design, synthesis and structure activity relationships of ureido-heterocyclic-carboxylic acids, *RSC Adv.,* **2014**, 4, 2177

279) Lu, C., Maurer, C.K., Kirsch, B., Steinbach, A., Hartmann, R.W. Overcoming unexpected functional inversion of PqsR antagonist in Pseudomonas aeruginosa led to the first in vivo potent anti-virulence agent targeting pqs quorum sensing, *Angewandte**,*** **2014,** *53*, 1109 –1112

280) Hinsberger, S., De Jong, J., Groh, M., Haupenthal, J., Hartmann, R.W. Benzamidobenzoic acids as potent PqsD inhibitors for the treatment of Pseudomonas aeruginosa infections: How to gain selectivity over RNA polymerase, *Eur. J. Med. Chem.,* **2014***, 76*, 343-351

281) Schmitt, C., Kail, D., Mariano, M., Empting, M., Weber, N., Paul, T., Hartmann, R.W., Engel, M. Design and synthesis of a library of lead-like 2,4-bisheterocyclic substituted thiophenes as selective Dyrk/Clk inhibitors, *PLoS One*, **2014***, 9,* e87851

282) Lu, C., Kirsch, B., Maurer, C.K., de Jong, J., Braunshausen, A., Steinbach, A., Hartmann**,** R.W. Optimization of anti-virulence PqsR antagonists regarding aqueous solubility and biological properties resulting in new insights into structure-activity relationships, *Eur. J. Med. Chem.,* **2014***, 79,* 173–183

283) Thomann, A., Boerger, C., Emtping, M., Hartmann, R.W. Microwave-assisted synthesis of 4-substituted 2-methylthiopyrimidines, *SYNLETT,* **2014***, 25: 935-938*

284) Hutter, M.C., Brengel, C., Henn, C., Zimmer, C., Hartmann, R.W., Steinbach, A., Negri, M. Computational results suggest that the catalytic machinery of PqsD works without a catalytic triad, *J. Mol. Model.,* **2014**, *20:* 2255

285) Laggai, S., Kessler, S., Boettcher, S., Gemperlein, K., Lederer, E., Mueller, R. Hartmann, R., Haybaeck, J., Kiemer, A. The IGF2 mRNA binding protein p62/IGF2BP2-2 induces fatty acid elongation as a critical feature of steatosis, *J. Lipid Res*., **2014**, *55*, 1087-1097

286) Abdelsamie, S. A., Bey, E., Hanke, N., Empting, M., Hartmann, R.W., Frotscher, M., Inhibition of 17β-HSD1: SAR of bicyclic substituted hydroxyphenylmethanones and discovery of new potent inhibitors with thioether linker, *Eur. J. Med. Chem.,* **2014***, 82,* 394-406

287) Hu, Q., Yin, L., Hartmann, R.W., Aldosterone synthase inhibitors as promising treatments for mineralocorticoid dependent cardiovascular and renal diseases*, J. Med. Chem.,* **2014,** *57*, 5011–5022

288) Yin, L., Hu, Q., Hartmann, R.W. Novel pyridyl or isoquinolinyl substituted indolines and indoles as potent and selective aldosterone synthase inhibitors, *J. Med. Chem.,* **2014**, *57*, 5179–5189

289) Zhu, W., Haupenthal, J., Groh, M., Fountain, M., Hartmann, R.W. New insights into the bacterial RNA polymerase inhibitor CBR703 1 as a starting point for optimization as an anti-infective agent, *Antimicrob Agents Chemother*, ***2014****, 58:7,* 4242-4245

290) Perspicace, E., Cozzoli, L., Gargano, E. M., Hanke, N., Carotti, A., Hartmann, R.W. Marchais-Oberwinkler, S. Novel, potent and selective 17β-hydroxysteroid dehydrogenase type 2 inhibitors as potential therapeutics for osteoporosis with dual human and mouse activities, *Eur. J. Med. Chem.,* **2014,** *83,* 317-337

291) Storz, M., Allegretta, G., Kirsch B., Empting, M., Hartmann, R. From *in vitro* to *in cellulo*: Structure-activity relationship of (2-nitrophenyl)methanol derivatives as inhibitors of PqsD in *Pseudomonas aeruginosa, OBC,* **2014,** *12*, 6094-6104

292) Nafee, N., Husari, A., Maurer, C.K., Lu, C., de Rossi, C., Steinbach, A., Hartmann, R.W., Lehr, C.M., Schneider, M. Antibiotic-free nanotherapeutics: Ultra-small mucus-penetrating solid lipid nanoparticles enhance the pulmonary delivery and anti-virulence efficacy of novel quorum sensing inhibitors, *J Control Release,* **2014***, 192*, 131-140

293) Hu, Q., Hartmann, R.W. The Renaissance of CYP17 Inhibitors for the treatment of prostate cancer, *Cancer Drug Design and Discovery*, Second Edition, **2014**, chapter 11, 319-356

294) Abdel-Halim, M., Diesel, B., Kiemer, A., Abadi, A., Hartmann, R., Engel, M. Discovery and optimization of 1,3,5-trisubstituted pyrazolinesas as potent and highly selective allosteric inhibitors of protein kinase C-ζ, *J. Med. Chem*., **2014**, *57*, 6513–6530

295) Schmitt, C., Miralinaghi, P., Mariano, M., Hartmann R., Engel, M. Hydroxybenzothiophene ketones are efficient pre-mRNA splicing modulators due to dual inhibition of Dyrk1A and Clk1/4, *ACS Med. Chem. Lett.*, **2014***, 5*, 963–967

296) Gargano, M., Perspicace, E., Hanke, N., Carotti, A., Marchais-Oberwinkler, S., Hartmann, R. Metabolic Stability Optimization and Metabolite Identification of 2,5-Thiophene Amide 17β-Hydroxysteroid Dehydrogenase Type 2 Inhibitors, *Eur. J. Med. Chem.,* **2014***, 87,* 203–219

297) Miralinaghi, P., Schmitt, C., Hartmann. R.W., Frotscher. M., Engel, M. 6-Hydroxybenzothiophene ketones: potent inhibitors of 17β- hydroxysteroid dehydrogenase type 1 (17β-HSD1) due to favorable molecule geometry and conformational pre-organization, *ChemMedChem,* **2014***, 9*, 2294-308

298) Zhu, W., Hu, Q., Hanke, N., vanKoppen, C., Hartmann, R. Potent 11β-Hydroxylase inhibitors with inverse metabolic stability in human plasma and hepatic S9 fractions to promote wound healing, *J. Med. Chem*., **2014**, *57*, 7811-7

299) Hüsecken, K., Hinsberger, S., Haupenthal, J., Hartmann, R.W. Surface plasmon resonance – more than a screening technology: Insights in the binding mode of σ70:core RNAP inhibitors, *Future Med. Chem.,* **2014**, *6*, 1551-65

300) Fruth, M., Plaza, A., Hinsberger, S., Sahner, J.H., Haupenthal, J., Bischoff, Jansen, R., Müller, R., Hartmann, R. Binding mode characterization of novel RNA polymerase inhibitors using a combined biochemical and NMR approach, *ACS Chem. Biol.,* **2014**, *9*, 2656-63

301) Allegretta, G., Weidel, E., Empting, M., Hartmann, R.W. Catechol-based substrates of chalcone synthase as a scaffold for novel inhibitors of PqsD, *Eur. J. Med. Chem.,* **2014,** 90C:351-359

302) Grombein, C., Hu, Q., Heim, R., Rau, S., Zimmer, C., Hartmann, R. 1-Phenylsulfinyl-3-(pyridin-3-yl)naphthalen-2-ols: A new class of potent and selective aldosterone synthase inhibitors, Eur.*J.Med.Chem.,* **2015***, 89*, 597e605

303) Al-Masoudi, N.A., Ali, D.S., Saeed, B., Hartmann, R.W., Engel, M., Rashid, S., Saeed, A. New CYP17 hydroxylase inhibitors: Synthesis, biological evaluation, QSAR, and molecular docking study of new pregnenolone analogs, Arch. Pharm. Chem. Life Sci. **2014**, *347*, 896–907

304) Stefanachi, A., Hanke, N., Pisani, L., Leonetti, F., Nicolotti, O., Cellamare, S., Hartmann, R., Carotti, A. Discovery of new 7-Substituted-4-imidazolylmethyl coumarins and 4'-substituted-2-Imidazolyl acetophenones open analogues as potent and selective inhibitors of steroid-11β-hydroxylase, Eur. *J. Med. Chem***,** **2015**, *89*, 106-114

305) Mariano, M., Schmitt, C., Miralinaghi, P., Catto, M., Hartmann, R.W., Carotti, A., Engel, M. First selective dual inhibitors of tau phosphorylation and beta-amyloid aggregation, two major pathogenic mechanisms in Alzheimer's disease, *ACS Chem. Neurosci.,* **doi: 10.1021/cn5001815**

306) Weidel, E., Negri, M., Empting, M., Hinsberger, S., Hartmann, R.W. How to compose compound libraries for hit 3 discovery – rationality-driven preselection or 4 random choice aiming at structural diversity? *Future Med. Chem., **accepted***

307) Grombein C.M., Hu, C., Rau, S., Zimmer, C., Hartmann, R.W. Heteroatom insertion into 3,4-Dihydro-1H-quinolin-2-ones leads to potent and selective inhibitors of human and rat aldosterone synthase, *EJMC*, ***doi: 10.1016/j.ejmech.2014.12.022***

308) Murthy J. N., Badrinarayan, P., Rao, A. R. R., Sastry N., Hartmann R.W., Design and synthesis of imidazolyl-1,2,3,4-tetrahydroquinolines as potent aromatase inhibitors, *ChemMedChem., **submitted***

309) Abdelsamie, A., Bey, E., Hanke, N., Zanter, E.-S., Gargano, E., Empting, M., Frotscher, M. Halogenated 17β-HSD1 Inhibitors: Discovery of Highly Potent and Metabolically Stable Compounds Enabling a Proof of Principle Study in Rodents, N.N.

310) Sahner, J.H., Sucipto, H., Wenzel, S.C., Groh, M., Hartmann, R.W., Müller, R. Advanced Mutasynthesis Studies on Natural α-Pyrone Antibiotics from Myxococcus fulvus, *RCS*, ***submitted***

311) Sahner, J.H., Empting, M., Kamal, A., Weidel, E., Börger, E., Hartmann, R. Exploring the chemical space of ureidothiophene-2-carboxylic acids as inhibitors of the quorum sensing enzyme PqsD from *Pseudomonas aeruginosa, Eur. J. Med. Chem.,* ***submitted***

Buchbeiträge:

"Quorum Sensing vs Quorum Quenching: A Battle with No End in Sight." Maurer, C., Lu, C., Empting, R., Hartmann, R.W. Synthetic Quorum Sensing Inhibitors (QSIs) Blocking Receptor Signaling or Signal Molecule Biosynthesis in Pseudomonas aeruginosa, Springer, erscheint 2015

Thomann, A., Boerger, C., Emtping, M., ChemInform Abstract: Microwave-Assisted Synthesis of 4-Substituted 2 Methylthiopyrimidines., ChemInform 11/2014; 45(45). DOI: 10.1002/chin.201445185